| 1 | ( L ) ASCORBATO DI CALCIO | - | - | - | - | [2] 96 96, 97 💬
|
| 2 | (+) erythromefloquine | - | - | - | - | [1] 46 46 💬
|
| 3 | (+) isomer of racemic mefloquine | [1] Mefloquine Mefloquine | [2] Mefloquine hydrochloride
Mefloquine hydrochloride
,
Mefloquine
💬
| - | - | [1] 46 46 💬
|
| 4 | (+) isomer or racemic mefloquine | [1] Mefloquine Mefloquine | [2] Mefloquine hydrochloride
Mefloquine hydrochloride
,
Mefloquine
💬
| - | - | [1] 46 46 💬
|
| 5 | (+)- Epicatechin | [1] Epicatechin Epicatechin | - | - | - | [1] 113 113 💬
|
| 6 | (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid | [1] Propanoic acid Propanoic acid | [3] Propionic acid
Propionic acid
,
Sodium propionate
,
Sodium propionate
💬
| - | - | [1] 271 271 💬
|
| 7 | (+)-Epicatechin | [1] Epicatechin Epicatechin | - | - | - | [1] 113 113 💬
|
| 8 | (+)erythromefloquine | - | - | - | - | [1] 46 46 💬
|
| 9 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | [1] 97 97 💬
|
| 10 | (-)-Epicatechin | [1] Epicatechin Epicatechin | - | - | - | [2] 86 86, 113 💬
|
| 11 | (-)-trans-delta-9-Tetrahydrocannabinol | [1] Dronabinol Dronabinol | [1] Dronabinol
Dronabinol
💬
| [2] CNR1 CNR1, CNR2 💬
| [4] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | [1] 13 13 💬
|
| 12 | (1-13C) Sodium Acetate | [2] Acetate Acetate, Sodium acetate | [1] Sodium acetate
Sodium acetate
💬
| - | - | [1] 251 251 💬
|
| 13 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | [1] 107 107 💬
|
| 14 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | [1] 107 107 💬
|
| 15 | (11C)PE2I | - | - | - | - | [1] 6 6 💬
|
| 16 | (18F)FPGLU | - | - | - | - | [1] 86 86 💬
|
| 17 | (1P)-3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-2'-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one | - | - | - | - | [1] 46 46 💬
|
| 18 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | [1] 11 11 💬
|
| 19 | (2)-epigallocatechin-3-gallate (EGCG) | [1] Epigallocatechin Epigallocatechin | - | - | - | [1] 8 8 💬
|
| 20 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | [1] 6 6 💬
|
| 21 | (2R)-2-Propyloctanoic acid | - | - | - | - | [1] 2 2 💬
|
| 22 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | [1] 309 309 💬
|
| 23 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | [1] 309 309 💬
|
| 24 | (3aR,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5-ol | - | - | - | - | [1] 6 6 💬
|
| 25 | (3aR,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5-ol phenylcarbamate, (2S,3S)-2,3-dihydroxybutanedioate (1:1) | - | - | - | - | [1] 6 6 💬
|
| 26 | (3beta, 5beta, 25R)-spirostan-3-ol | - | - | - | - | [1] 6 6 💬
|
| 27 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | [1] 46 46 💬
|
| 28 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | [1] 46 46 💬
|
| 29 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | [1] 46 46 💬
|
| 30 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | [1] 46 46 💬
|
| 31 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | [1] 46 46 💬
|
| 32 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | [1] 46 46 💬
|
| 33 | (3ß, 5ß, 25R)-spirostan-3-ol | - | - | - | - | [1] 6 6 💬
|
| 34 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | [1] 231 231 💬
|
| 35 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | [1] 79 79 💬
|
| 36 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | [1] 2 2 💬
|
| 37 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | [1] 6 6 💬
|
| 38 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | [1] 301 301 💬
|
| 39 | (CDP6038 | - | - | - | - | [1] 46 46 💬
|
| 40 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | [1] 161 161 💬
|
| 41 | (E)-3-[2,6-Dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]-thiazol-2-ylcarbamoyl]-phenyl]-2-methylacrylic acid | - | - | - | - | [1] 63 63 💬
|
| 42 | (E)-3-[2,6-Dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]-thiazol-2-ylcarbamoyl]-phenyl]-2methylacrylic acid | - | - | - | - | [1] 63 63 💬
|
| 43 | (IM) AVONEX® | - | - | - | - | [1] 13 13 💬
|
| 44 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | [1] 6 6 💬
|
| 45 | (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4- yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one | - | - | - | - | [1] 46 46 💬
|
| 46 | (Pyr1)apelin-13 | [1] Apelin Apelin | - | - | - | [1] 86 86 💬
|
| 47 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | [1] 13 13 💬
|
| 48 | (R)-(-)-2-Propyloctaroic acid | - | - | - | - | [1] 2 2 💬
|
| 49 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | - | - | - | - | [1] 75 75 💬
|
| 50 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)( 4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 51 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 52 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 53 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 54 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8- HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN- 4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 55 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | - | - | - | - | [1] 75 75 💬
|
| 56 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | - | - | - | - | [1] 97 97 💬
|
| 57 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | [1] 127 127 💬
|
| 58 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | [1] Pyrazole Pyrazole | - | - | - | [1] 58 58 💬
|
| 59 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | [1] Pyrazole Pyrazole | - | - | - | [1] 58 58 💬
|
| 60 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | [1] 58 58 💬
|
| 61 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | [1] Piperazine Piperazine | [5] Piperazine
Piperazine
,
Piperazine phosphate
,
Piperazine citrate
,
Piperazine adipate
,
Piperazine hexahydrate
💬
| - | - | [1] 272 272 💬
|
| 62 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | [1] Piperazine Piperazine | [5] Piperazine
Piperazine
,
Piperazine phosphate
,
Piperazine citrate
,
Piperazine adipate
,
Piperazine hexahydrate
💬
| - | - | [1] 272 272 💬
|
| 63 | (R)-troloxamide quinone | - | - | - | - | [1] 6 6 💬
|
| 64 | (RS)-baclofen | [1] Baclofen Baclofen | [1] Baclofen
Baclofen
💬
| [2] GABBR1 GABBR1, GABBR2 💬
| [8] Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | [1] 10 10 💬
|
| 65 | (RS)-baclofen, naltrexone hydrochloride and D-sorbitol | [3] Baclofen Baclofen, Naltrexone, Sorbitol | [4] Sorbitol solution
Sorbitol solution
,
Baclofen
,
Naltrexone hydrochloride
,
Naltrexone
💬
| [5] GABBR1 GABBR1, GABBR2, OPRD1, OPRK1, OPRM1 💬
| [11] Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 10 10 💬
|
| 66 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | [1] 6 6 💬
|
| 67 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | [1] 6 6 💬
|
| 68 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | [1] 97 97 💬
|
| 69 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | [1] 86 86 💬
|
| 70 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | [1] 240 240 💬
|
| 71 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | [1] 86 86 💬
|
| 72 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | [1] 86 86 💬
|
| 73 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | [1] 284 284 💬
|
| 74 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | [2] Magnesium Magnesium, Magnesium hydroxide | [1] Magnesium hydroxide
Magnesium hydroxide
💬
| - | - | [1] 284 284 💬
|
| 75 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | [1] 284 284 💬
|
| 76 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | [2] Magnesium Magnesium, Magnesium hydroxide | [1] Magnesium hydroxide
Magnesium hydroxide
💬
| - | - | [1] 284 284 💬
|
| 77 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | [1] 97 97 💬
|
| 78 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | [1] 97 97 💬
|
| 79 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | [1] 97 97 💬
|
| 80 | (S)-N-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide | [1] Acetamide Acetamide | - | - | - | [1] 65 65 💬
|
| 81 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | [1] 97 97 💬
|
| 82 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | [1] 97 97 💬
|
| 83 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | [1] 97 97 💬
|
| 84 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | [1] 41 41 💬
|
| 85 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | [1] 41 41 💬
|
| 86 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | - | - | - | - | [1] 86 86 💬
|
| 87 | - Skin biopsy - Urine sample - Blood sample | - | - | - | - | [1] 51 51 💬
|
| 88 | -aminosalicylic acid | [1] Aminosalicylic acid Aminosalicylic acid | [1] Aminosalicylic acid
Aminosalicylic acid
💬
| - | - | [2] 96 96, 97 💬
|
| 89 | -Current Sponsor code: BIIB067 (ISIS 666853)Other descriptive name: BIIB067Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 6.7-Pharmaceutical form of the placebo: Solution for injectionRoute of administration of the placebo: Intrathecal use | - | - | - | - | [1] 2 2 💬
|
| 90 | .Nusinersen | [1] Nusinersen Nusinersen | [2] Nusinersen sodium
Nusinersen sodium
,
Nusinersen
💬
| - | - | [1] 3 3 💬
|
| 91 | 0 g/d CICR-NAM (blinded) | - | - | - | - | [1] 97 97 💬
|
| 92 | 0 mg Prednisone | [1] Prednisone Prednisone | [1] Prednisone
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 44 44 💬
|
| 93 | 0 mg tropicamide | [1] Tropicamide Tropicamide | [1] Tropicamide
Tropicamide
💬
| [5] CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬
| [14] Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 94 | 0,25 mg RPC1063 | - | - | - | - | [1] 96 96 💬
|
| 95 | 0,35% povidone-iodine solution lavage | [3] Iodine Iodine, Povidone, Povidone-iodine | [3] Iodine
Iodine
,
Povidone-iodine
,
Povidone
💬
| - | - | [1] 46 46 💬
|
| 96 | 0,5 mg Fingolimod | [1] Fingolimod Fingolimod | [3] Fingolimod hydrochloride
Fingolimod hydrochloride
,
Fingolimod
,
Fingolimod lauryl sulfate
💬
| [1] S1PR1 S1PR1 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 97 | 0,5 mg Prevenar i.m. | - | - | - | - | [1] 51 51 💬
|
| 98 | 0,5 mg seasonal influenza vaccine i.m. | - | - | - | - | [1] 51 51 💬
|
| 99 | 0.005% Lacripep | [1] Lacripep Lacripep | - | - | - | [1] 53 53 💬
|
| 100 | 0.01% Lacripep | [1] Lacripep Lacripep | - | - | - | [1] 53 53 💬
|
| 101 | 0.02% Fm, SH | - | - | - | - | [1] 53 53 💬
|
| 102 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | [1] 53 53 💬
|
| 103 | 0.02% Fm, SH, AS | - | - | - | - | [1] 53 53 💬
|
| 104 | 0.03% using a foot pump | - | - | - | - | [1] 97 97 💬
|
| 105 | 0.04 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 106 | 0.05% Cyclosporine Eye Drops | [1] Cyclosporine Cyclosporine | [1] Cyclosporine
Cyclosporine
💬
| [5] PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬
| [33] Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 53 53 💬
|
| 107 | 0.05%cyclosporin eye drop | - | - | - | - | [1] 38 38 💬
|
| 108 | 0.08 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 109 | 0.12% saline | - | - | - | - | [1] 299 299 💬
|
| 110 | 0.2 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 111 | 0.25 mg RPC103 | - | - | - | - | [1] 97 97 💬
|
| 112 | 0.25 mg RPC1063 | - | - | - | - | [3] 13 13, 96, 97 💬
|
| 113 | 0.25mg RPC103 | - | - | - | - | [1] 97 97 💬
|
| 114 | 0.25mg RPC1063 | - | - | - | - | [2] 13 13, 97 💬
|
| 115 | 0.3 mg tropicamide | [1] Tropicamide Tropicamide | [1] Tropicamide
Tropicamide
💬
| [5] CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬
| [14] Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 116 | 0.4 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 117 | 0.4mL prefilled syringes | - | - | - | - | [1] 107 107 💬
|
| 118 | 0.5 mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 119 | 0.5 mg RPC1063 | - | - | - | - | [2] 13 13, 97 💬
|
| 120 | 0.5% marcaine | - | - | - | - | [1] 70 70 💬
|
| 121 | 0.5mg RPC1063 | - | - | - | - | [1] 13 13 💬
|
| 122 | 0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery. | [2] Esketamine Esketamine, Remifentanil | [4] Remifentanil hydrochloride
Remifentanil hydrochloride
,
Esketamine
,
Remifentanil
,
Esketamine hydrochloride
💬
| [6] GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, OPRM1 💬
| [24] Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Estrogen signaling pathway, Glutamatergic synapse, Hormone signaling, Huntington disease, Long-term potentiation, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 123 | 0.6 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 124 | 0.7mL prefilled syringes | - | - | - | - | [1] 107 107 💬
|
| 125 | 0.8 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 126 | 0.9 % NaCl | - | - | - | - | [1] 124 124 💬
|
| 127 | 0.9% Chloride Injection Sodium | - | - | - | - | [1] 13 13 💬
|
| 128 | 0.9% Isotonic Saline (IS) | - | - | - | - | [1] 299 299 💬
|
| 129 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | [1] 299 299 💬
|
| 130 | 0.9% NaCl | - | - | - | - | [1] 79 79 💬
|
| 131 | 0.9% Normal Saline | - | - | - | - | [1] 35 35 💬
|
| 132 | 0.9% normal saline (control) | - | - | - | - | [1] 299 299 💬
|
| 133 | 0.9% physiological saline | - | - | - | - | [1] 266 266 💬
|
| 134 | 0.9% saline | - | - | - | - | [2] 6 6, 70 💬
|
| 135 | 0.9% sodium chloride | [1] Sodium chloride Sodium chloride | [1] Sodium chloride
Sodium chloride
💬
| - | - | [5] 6 6, 14, 51, 53, 96 💬
|
| 136 | 0.9% sodium chloride (normal saline) | [1] Sodium chloride Sodium chloride | [1] Sodium chloride
Sodium chloride
💬
| - | - | [2] 6 6, 85 💬
|
| 137 | 0.9% Sodium Chloride Injection | [1] Sodium chloride Sodium chloride | [1] Sodium chloride
Sodium chloride
💬
| - | - | [2] 70 70, 168 💬
|
| 138 | 0.9% w/v isotonic sodium chloride solution | [1] Sodium chloride Sodium chloride | [1] Sodium chloride
Sodium chloride
💬
| - | - | [1] 50 50 💬
|
| 139 | 0.9% w/v sodium chloride solution | [1] Sodium chloride Sodium chloride | [1] Sodium chloride
Sodium chloride
💬
| - | - | [1] 299 299 💬
|
| 140 | 00000 | - | - | - | - | [2] 6 6, 96 💬
|
| 141 | 000000 | - | - | - | - | [1] 6 6 💬
|
| 142 | 0002-8971 | - | - | - | - | [1] 70 70 💬
|
| 143 | 00070500 | - | - | - | - | [1] 60 60 💬
|
| 144 | 00201600 | - | - | - | - | [1] 229 229 💬
|
| 145 | 00244301 | - | - | - | - | [1] 274 274 💬
|
| 146 | 00258901 | - | - | - | - | [1] 85 85 💬
|
| 147 | 00305800 | - | - | - | - | [2] 53 53, 160 💬
|
| 148 | 00319301 | - | - | - | - | [1] 60 60 💬
|
| 149 | 00322900 | - | - | - | - | [1] 85 85 💬
|
| 150 | 009-0 | - | - | - | - | [1] 6 6 💬
|
| 151 | 009-1 | - | - | - | - | [1] 6 6 💬
|
| 152 | 009-2 | - | - | - | - | [1] 6 6 💬
|
| 153 | 009-3 | - | - | - | - | [1] 6 6 💬
|
| 154 | 009-4 | - | - | - | - | [1] 6 6 💬
|
| 155 | 009-5 | - | - | - | - | [1] 6 6 💬
|
| 156 | 009-A0 | - | - | - | - | [1] 6 6 💬
|
| 157 | 009-A1 | - | - | - | - | [1] 6 6 💬
|
| 158 | 009-A2 | - | - | - | - | [1] 6 6 💬
|
| 159 | 009-A3 | - | - | - | - | [1] 6 6 💬
|
| 160 | 0109-0012A 100 mg/ml | - | - | - | - | [1] 46 46 💬
|
| 161 | 0109-0012A 25 mg/ml | - | - | - | - | [1] 46 46 💬
|
| 162 | 0109-0012A 50 mg/ml | - | - | - | - | [1] 46 46 💬
|
| 163 | 0114-0006B | - | - | - | - | [2] 46 46, 96 💬
|
| 164 | 02458357 | - | - | - | - | [1] 96 96 💬
|
| 165 | 033841 | - | - | - | - | [1] 299 299 💬
|
| 166 | 0881 | - | - | - | - | [2] 46 46, 271 💬
|
| 167 | 1 - Andrographis paniculata p/st extract | - | - | - | - | [1] 13 13 💬
|
| 168 | 1 infusion of MSC | - | - | - | - | [1] 51 51 💬
|
| 169 | 1 mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 170 | 1 mg QD to 15 mg QD PF-06649751 | - | - | - | - | [1] 6 6 💬
|
| 171 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | - | - | - | - | [1] 6 6 💬
|
| 172 | 1 mg RPC1063 | - | - | - | - | [2] 13 13, 97 💬
|
| 173 | 1 mg tropicamide | [1] Tropicamide Tropicamide | [1] Tropicamide
Tropicamide
💬
| [5] CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬
| [14] Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 174 | 1 mg/kg CNTO 136 | - | - | - | - | [1] 49 49 💬
|
| 175 | 1 ml 0.9 % NaCl | - | - | - | - | [1] 46 46 💬
|
| 176 | 1 ml reconstituted solution contains 5 mg rabbit, anti-human thymocyte immunoglobulin. | [1] Rabbit Rabbit | - | - | - | [1] 60 60 💬
|
| 177 | 1 Serving of broccoli sprouts | [1] Broccoli Broccoli | - | - | - | [1] 97 97 💬
|
| 178 | 1% lignocaine | - | - | - | - | [1] 84 84 💬
|
| 179 | 1% Steroid Cream | - | - | - | - | [1] 13 13 💬
|
| 180 | 1) Inosine 5'-monophosphate | [1] Inosine Inosine | [1] Inosine
Inosine
💬
| - | - | [1] 17 17 💬
|
| 181 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | - | - | - | - | [1] 79 79 💬
|
| 182 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | - | - | - | - | [1] 299 299 💬
|
| 183 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | [1] 46 46 💬
|
| 184 | 1- Deoxygalactonojirimycin | - | - | - | - | [1] 19 19 💬
|
| 185 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | [1] Piperazine Piperazine | [5] Piperazine
Piperazine
,
Piperazine phosphate
,
Piperazine citrate
,
Piperazine adipate
,
Piperazine hexahydrate
💬
| - | - | [1] 58 58 💬
|
| 186 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | [1] 17 17 💬
|
| 187 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | [1] Indole Indole | - | - | - | [1] 51 51 💬
|
| 188 | 1-20190 | - | - | - | - | [1] 93 93 💬
|
| 189 | 1-22460 | - | - | - | - | [1] 51 51 💬
|
| 190 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | [1] Quinoline Quinoline | - | - | - | [1] 299 299 💬
|
| 191 | 1-deoxygalactonojirimycin hydrochloride | [1] Migalastat Migalastat | [2] Migalastat hydrochloride
Migalastat hydrochloride
,
Migalastat
💬
| [1] GLA GLA 💬
| [5] Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome biogenesis, Sphingolipid metabolism 💬 | [1] 19 19 💬
|
| 192 | 1-deoxynojirimycin hydrochloride | [1] Duvoglustat Duvoglustat | [2] Duvoglustat
Duvoglustat
,
Duvoglustat hydrochloride
💬
| [1] GAA GAA 💬
| [3] Galactose metabolism Galactose metabolism, Lysosome biogenesis, Starch and sucrose metabolism 💬 | [1] 256 256 💬
|
| 193 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | [1] 13 13 💬
|
| 194 | 1. Tesofensine (NS 2330) | [1] Tesofensine Tesofensine | - | - | - | [1] 6 6 💬
|
| 195 | 1.0 g Vancomycin powder into the wound | [1] Vancomycin Vancomycin | [2] Vancomycin
Vancomycin
,
Vancomycin hydrochloride
💬
| - | - | [1] 46 46 💬
|
| 196 | 1.0 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 197 | 1.0 mg rasagiline mesylate | [1] Rasagiline Rasagiline | [3] Rasagiline mesylate
Rasagiline mesylate
,
Rasagiline
,
Rasagiline tartrate
💬
| [1] MAOB MAOB 💬
| [13] Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | [1] 6 6 💬
|
| 198 | 1.0 mg RPC103 | - | - | - | - | [1] 97 97 💬
|
| 199 | 1.0 mg RPC1063 | - | - | - | - | [1] 97 97 💬
|
| 200 | 1.0 MIU IL-2 per day | - | - | - | - | [1] 2 2 💬
|
| 201 | 1.0mg RPC1063 | - | - | - | - | [1] 13 13 💬
|
| 202 | 1.2 mg Lu AE04621 | - | - | - | - | [1] 6 6 💬
|
| 203 | 1.2 mg ZGN-440 for injectable suspension | - | - | - | - | [1] 193 193 💬
|
| 204 | 1.5 x 10^6 UC-MSC + CM | - | - | - | - | [1] 90 90 💬
|
| 205 | 1.8 mg ZGN-440 for injectable suspension | - | - | - | - | [1] 193 193 💬
|
| 206 | 1.Remicade | - | - | - | - | [1] 97 97 💬
|
| 207 | 10 mg | - | - | - | - | [1] 96 96 💬
|
| 208 | 10 mg Natura-alpha capsule | - | - | - | - | [1] 97 97 💬
|
| 209 | 10 mg/kg CM-101 | [1] CM-101 CM-101 | - | - | - | [1] 51 51 💬
|
| 210 | 10 mg/kg CNTO 136 | - | - | - | - | [1] 49 49 💬
|
| 211 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | - | - | - | - | [1] 13 13 💬
|
| 212 | 10% intravenous immunoglobulin (IVIg) | - | - | - | - | [1] 14 14 💬
|
| 213 | 10% liquid formulation of human immunoglobulin | - | - | - | - | [1] 14 14 💬
|
| 214 | 10% nifedipine cream | [1] Nifedipine Nifedipine | [1] Nifedipine
Nifedipine
💬
| [4] CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬
| [37] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 50 50 💬
|
| 215 | 10% Nitroglycerine in Propylene Glycol, USP | [1] Propylene glycol Propylene glycol | [2] Propylene glycol
Propylene glycol
,
Propylene glycol diacetate
💬
| - | - | [1] 51 51 💬
|
| 216 | 10% urea lotion plus 1% cannabidiol | [1] Cannabidiol Cannabidiol | [1] Cannabidiol
Cannabidiol
💬
| [2] CNR1 CNR1, CNR2 💬
| [4] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | [1] 51 51 💬
|
| 217 | 10-mg dose of E5501 2G tablet | - | - | - | - | [1] 63 63 💬
|
| 218 | 10-mg dose of E5501 cyclodextrin oral solution | - | - | - | - | [1] 63 63 💬
|
| 219 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | [1] 63 63 💬
|
| 220 | 10-mg dose of E5501-P21% powder | - | - | - | - | [1] 63 63 💬
|
| 221 | 10-nitro-9(E)-octadec-9-enoic acid | [1] CXA-10 CXA-10 | - | - | - | [1] 86 86 💬
|
| 222 | 100 | - | - | - | - | [2] 6 6, 97 💬
|
| 223 | 100 mg | - | - | - | - | [1] 97 97 💬
|
| 224 | 100 mg AP1189 | - | - | - | - | [2] 46 46, 222 💬
|
| 225 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 226 | 100 mg ELX /50 mg TEZ /75 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 227 | 100 mg ELX/50 mg TEZ /75 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 228 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | [1] 299 299 💬
|
| 229 | 100 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 230 | 100 mg TEZ/150 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 231 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 232 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 233 | 100 mg/m2 dose | - | - | - | - | [1] 299 299 💬
|
| 234 | 100 µg Brimonidine Tartrate Implant | [1] Brimonidine Brimonidine | [2] Brimonidine tartrate
Brimonidine tartrate
,
Brimonidine
💬
| [3] ADRA2A ADRA2A, ADRA2B, ADRA2C 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | [1] 90 90 💬
|
| 235 | 100 µg KIO-301 | [1] KIO-301 KIO-301 | - | - | - | [1] 90 90 💬
|
| 236 | 100% of individual calory requirement | - | - | - | - | [1] 2 2 💬
|
| 237 | 100% Oxygen | [1] Oxygen Oxygen | [1] Oxygen
Oxygen
💬
| - | - | [6] 13 13, 15, 36, 96, 97, 269 💬
|
| 238 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 239 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 240 | 100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 241 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 242 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 243 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDCProduct Code: VX-445/TEZ/IVAPharmaceutical Form: Film-coated tabletINN or Proposed INN: elexacaftorCAS Number: 2216712-66-0Current Sponsor code: VX-445Other descriptive name: VX-445Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 100-INN or Proposed INN: TEZACAFTORCAS Number: 1152311-62-0Current Sponsor code: VX-661Other descriptive name: TEZConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 50-INN or Proposed INN: IVACAFTORCAS Number: 873054-44-5Current Sponsor code: VX-770Other descriptive name: IVAConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral use | - | - | - | - | [1] 299 299 💬
|
| 244 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | [1] 299 299 💬
|
| 245 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 246 | 1000 IU D3 | - | - | - | - | [1] 96 96 💬
|
| 247 | 10000IU vitamin D | [1] Vitamin D Vitamin D | - | - | - | [1] 13 13 💬
|
| 248 | 1000mg acetaminophen | [1] Acetaminophen Acetaminophen | [1] Acetaminophen
Acetaminophen
💬
| [2] PTGS1 PTGS1, PTGS2 💬
| [23] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Efferocytosis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 13 13 💬
|
| 249 | 1000mg RTX Group | - | - | - | - | [1] 46 46 💬
|
| 250 | 100g ELX / 50mg TEZ / 75mg IVA | - | - | - | - | [1] 299 299 💬
|
| 251 | 100mcg rhPTH(1-84) | - | - | - | - | [1] 235 235 💬
|
| 252 | 100mg ELX/50mg TEZ /75mg IVA | - | - | - | - | [1] 299 299 💬
|
| 253 | 100mg ELX/50mg TEZ /75mg IVAProduct Code: VX-445/TEZ/IVAPharmaceutical Form: Film-coated tabletINN or Proposed INN: ElexacaftorCAS Number: 2216712-66-0Current Sponsor code: VX-445Other descriptive name: ELXConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 100-INN or Proposed INN: TezacaftorCAS Number: 1152311-62-0Current Sponsor code: VX-661Other descriptive name: TEZConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 50-INN or Proposed INN: IvacaftorCAS Number: 873054-44-5Current Sponsor code: VX-770Other descriptive name: IVAConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Pharmaceutical form of the placebo: TabletRoute of administration of the placebo: Oral useProduct Name: 150mg IVACAFTORProduct Code: VX-770Pharmaceutical Form: Film-coated tabletINN or Proposed INN: IvacaftorCAS Number: 873054-44-5Current Sponsor code: VX-770Other descriptive name: IVAConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 150-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral useProduct Name: 75-mg IVACAFTORProduct Code: VX-770Pharmaceutical Form: Film-coated tabletINN or Proposed INN: IvacaftorCAS Number: 873054-44-5Current Sponsor code: VX-770Other descriptive name: IVAConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Pharmaceutical form of the placebo: Film-coated tabletRoute of administration of the placebo: Oral useProduct Name: 50 mg ELX/25 mg TEZ/37.5 mg IVAProduct Code: VX-445/TEZ/IVAPharmaceutical Form: Film-coated tabletINN or Proposed INN: IvacaftorCAS Number: 873054-44-5Current Sponsor code: VX- | - | - | - | - | [1] 299 299 💬
|
| 254 | 100mg FHND1002 | - | - | - | - | [1] 2 2 💬
|
| 255 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | [1] 299 299 💬
|
| 256 | 1064nm laser | - | - | - | - | [1] 34 34 💬
|
| 257 | 1064nm Nd:YAG laser | - | - | - | - | [1] 34 34 💬
|
| 258 | 10mg lenalidomide | [1] Lenalidomide Lenalidomide | [1] Lenalidomide
Lenalidomide
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 300 300 💬
|
| 259 | 11-beta-hydroxysteroid dehydrogenase type 1 | - | - | - | - | [1] 75 75 💬
|
| 260 | 11-ß-hydroxysteroid dehydrogenase type 1 | - | - | - | - | [1] 75 75 💬
|
| 261 | 111JC101 | - | - | - | - | [1] 25 25 💬
|
| 262 | 118-42-3 | - | - | - | - | [1] 46 46 💬
|
| 263 | 11C-acetate | [1] Acetate Acetate | - | - | - | [2] 86 86, 88 💬
|
| 264 | 11C-BMS-986196 | - | - | - | - | [1] 13 13 💬
|
| 265 | 11C-CSar | - | - | - | - | [2] 93 93, 94 💬
|
| 266 | 11C-flumazenil | [1] Flumazenil Flumazenil | [1] Flumazenil
Flumazenil
💬
| [16] GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬
| [9] Cadherin signaling Cadherin signaling, GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | [1] 206 206 💬
|
| 267 | 11C-MC1 | - | - | - | - | [2] 6 6, 13 💬
|
| 268 | 11C-Methylreboxetine (11C-MRB) | - | - | - | - | [2] 6 6, 17 💬
|
| 269 | 11C-PBR28 | - | - | - | - | [2] 6 6, 13 💬
|
| 270 | 11C-PiB | - | - | - | - | [2] 6 6, 13 💬
|
| 271 | 11C-PS13 | - | - | - | - | [2] 6 6, 13 💬
|
| 272 | 11C-Raclopride | [1] Raclopride Raclopride | - | - | - | [1] 6 6 💬
|
| 273 | 12 lead electrocardiogram | - | - | - | - | [1] 19 19 💬
|
| 274 | 12 mg/kg GSK2402968 | - | - | - | - | [1] 113 113 💬
|
| 275 | 12-Lead ECG | - | - | - | - | [2] 140 140, 144 💬
|
| 276 | 120 mg sodium nitrite inhalation solution | [2] Nitrite Nitrite, Nitrous acid | [1] Sodium nitrite
Sodium nitrite
💬
| - | - | [1] 86 86 💬
|
| 277 | 120% of individual calory requirement | - | - | - | - | [1] 2 2 💬
|
| 278 | 124I-AT-01 | - | - | - | - | [1] 28 28 💬
|
| 279 | 124I-AT03 | - | - | - | - | [1] 28 28 💬
|
| 280 | 124I-evuzamitide | - | - | - | - | [1] 70 70 💬
|
| 281 | 124I-labeled monoclonal antibody Mu 11-1F4 | - | - | - | - | [1] 28 28 💬
|
| 282 | 124I-p5+14 Injection | - | - | - | - | [1] 28 28 💬
|
| 283 | 125 | - | - | - | - | [1] 6 6 💬
|
| 284 | 129Xe | - | - | - | - | [1] 299 299 💬
|
| 285 | 129Xe Hyperpolarized | - | - | - | - | [1] 86 86 💬
|
| 286 | 129Xe Small and Large Human Lung Coil | - | - | - | - | [1] 299 299 💬
|
| 287 | 12S-IT | - | - | - | - | [1] 19 19 💬
|
| 288 | 13 valent conjugated pneumococcal vaccine | - | - | - | - | [1] 265 265 💬
|
| 289 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | [1] 93 93 💬
|
| 290 | 13-PCV Booster | - | - | - | - | [1] 13 13 💬
|
| 291 | 13-valent pneumococcal conjugate vaccine | - | - | - | - | [2] 46 46, 53 💬
|
| 292 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | [1] 13 13 💬
|
| 293 | 13-valent pneumococcal conjugated vaccine (PCV13) | - | - | - | - | [2] 96 96, 97 💬
|
| 294 | 13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT) | [1] Spirulina platensis Spirulina platensis | - | - | - | [1] 299 299 💬
|
| 295 | 13N-Ammonia | [1] Ammonia Ammonia | [1] Ammonia solution, strong
Ammonia solution, strong
💬
| - | - | [2] 6 6, 17 💬
|
| 296 | 13NH3 PET/CT scan | - | - | - | - | [1] 84 84 💬
|
| 297 | 146368 | - | - | - | - | [1] 271 271 💬
|
| 298 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | - | - | - | - | [1] 13 13 💬
|
| 299 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | - | - | - | - | [1] 6 6 💬
|
| 300 | 15 mg QD PF-06649751 | - | - | - | - | [1] 6 6 💬
|
| 301 | 15 mg sodium nitrite inhalation solution | [2] Nitrite Nitrite, Nitrous acid | [1] Sodium nitrite
Sodium nitrite
💬
| - | - | [1] 86 86 💬
|
| 302 | 15 ml Bupivacaine Hcl 0.25% injection | [1] Bupivacaine Bupivacaine | [2] Bupivacaine hydrochloride
Bupivacaine hydrochloride
,
Bupivacaine
💬
| [6] SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN8A, SCN9A 💬
| [5] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Cadherin signaling, Dopaminergic synapse, IgSF CAM signaling, Taste transduction 💬 | [1] 71 71 💬
|
| 303 | 15 or 45 mg | - | - | - | - | [1] 67 67 💬
|
| 304 | 15-0 H20 | - | - | - | - | [2] 6 6, 19 💬
|
| 305 | 15-day taper prednisone | [1] Prednisone Prednisone | [1] Prednisone
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 46 46 💬
|
| 306 | 15-O labeled water | [1] Water Water | [1] Water
Water
💬
| - | - | [1] 46 46 💬
|
| 307 | 150 mg double-blinded secukinumab | [1] Secukinumab Secukinumab | [1] Secukinumab
Secukinumab
💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
| 308 | 150 mg FHND1002 | - | - | - | - | [1] 2 2 💬
|
| 309 | 150 mg GSK1265744B | - | - | - | - | [1] 265 265 💬
|
| 310 | 150 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 311 | 150 mg open-label secukinumab | [1] Secukinumab Secukinumab | [1] Secukinumab
Secukinumab
💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
| 312 | 150% of their routine home dopaminergic medications dose right in the clinic | - | - | - | - | [1] 6 6 💬
|
| 313 | 150-day taper prednisone | [1] Prednisone Prednisone | [1] Prednisone
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 46 46 💬
|
| 314 | 150-mg IVACAFTOR | [1] Ivacaftor Ivacaftor | [1] Ivacaftor
Ivacaftor
💬
| [1] CFTR CFTR 💬
| [9] ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Phagocytosis, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | [1] 299 299 💬
|
| 315 | 1500mg mesalazine pellets | [1] Mesalazine Mesalazine | [1] Mesalamine
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 316 | 150] mg per day | - | - | - | - | [1] 57 57 💬
|
| 317 | 150mg CXA-10 | [1] CXA-10 CXA-10 | - | - | - | [1] 86 86 💬
|
| 318 | 150mg IVACAFTOR | [1] Ivacaftor Ivacaftor | [1] Ivacaftor
Ivacaftor
💬
| [1] CFTR CFTR 💬
| [9] ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Phagocytosis, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | [1] 299 299 💬
|
| 319 | 15N ammonium chloride (15NH4Cl) | [1] Ammonium chloride Ammonium chloride | [1] Ammonium chloride
Ammonium chloride
💬
| - | - | [1] 251 251 💬
|
| 320 | 15N2-tofacitinib | [1] Tofacitinib Tofacitinib | [2] Tofacitinib citrate
Tofacitinib citrate
,
Tofacitinib
💬
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬
| [39] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Efferocytosis, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 97 97 💬
|
| 321 | 15O H2O | - | - | - | - | [1] 6 6 💬
|
| 322 | 16,5% Cutaquig | - | - | - | - | [1] 65 65 💬
|
| 323 | 1629063-78-0 | - | - | - | - | [1] 19 19 💬
|
| 324 | 1643368-58-4 | - | - | - | - | [2] 53 53, 160 💬
|
| 325 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | [1] 41 41 💬
|
| 326 | 171 | - | - | - | - | [1] 86 86 💬
|
| 327 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | [1] 75 75 💬
|
| 328 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | [1] 75 75 💬
|
| 329 | 18 FDG | - | - | - | - | [1] 145 145 💬
|
| 330 | 18-22mg/kg/d Ursodeoxycholic | - | - | - | - | [1] 93 93 💬
|
| 331 | 18-FDTBZ | - | - | - | - | [1] 6 6 💬
|
| 332 | 18F florbetaben | - | - | - | - | [1] 6 6 💬
|
| 333 | 18F- DTBZ | - | - | - | - | [1] 6 6 💬
|
| 334 | 18F-AV-133 | - | - | - | - | [1] 6 6 💬
|
| 335 | 18F-AV-1451 | - | - | - | - | [3] 5 5, 7, 127 💬
|
| 336 | 18F-AV-45 | - | - | - | - | [2] 6 6, 127 💬
|
| 337 | 18F-DOPA | - | - | - | - | [3] 6 6, 17, 75 💬
|
| 338 | 18F-DOPA PET | - | - | - | - | [1] 6 6 💬
|
| 339 | 18F-Dopamine | [1] Dopamine Dopamine | [2] Dopamine hydrochloride
Dopamine hydrochloride
,
Dopamine
💬
| [5] DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬
| [13] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | [2] 6 6, 17 💬
|
| 340 | 18F-DPA-714 and 18F-FDG | - | - | - | - | [1] 13 13 💬
|
| 341 | 18F-DTBZ | - | - | - | - | [1] 6 6 💬
|
| 342 | 18F-DTBZ AV-133 | - | - | - | - | [1] 6 6 💬
|
| 343 | 18F-FDG | - | - | - | - | [3] 6 6, 127, 300 💬
|
| 344 | 18f-florbetaben | - | - | - | - | [1] 6 6 💬
|
| 345 | 18F-Fluoro-L-dopa | - | - | - | - | [1] 6 6 💬
|
| 346 | 18F-fluorodeoxyglucose | - | - | - | - | [1] 84 84 💬
|
| 347 | 18F-FSPG | - | - | - | - | [1] 84 84 💬
|
| 348 | 18F-FTC-146 | - | - | - | - | [1] 206 206 💬
|
| 349 | 18F-MFBG | - | - | - | - | [1] 6 6 💬
|
| 350 | 18F-OP-801 | - | - | - | - | [3] 2 2, 6, 13 💬
|
| 351 | 18F-PBR06 | - | - | - | - | [1] 17 17 💬
|
| 352 | 18F-PM-PBB3 | - | - | - | - | [1] 13 13 💬
|
| 353 | 18F-RO6958948 | - | - | - | - | [3] 5 5, 7, 127 💬
|
| 354 | 18F-SMBT-1 | - | - | - | - | [1] 6 6 💬
|
| 355 | 18FDG PET scan | - | - | - | - | [1] 41 41 💬
|
| 356 | 18FDG PET/CT scan | - | - | - | - | [1] 84 84 💬
|
| 357 | 19 nor vitamin d | [1] Vitamin D Vitamin D | - | - | - | [1] 13 13 💬
|
| 358 | 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab) | [4] Filgotinib Filgotinib, Infliximab, Ustekinumab, Vedolizumab | [5] Infliximab
Infliximab
,
Vedolizumab
,
Ustekinumab
,
Filgotinib
,
Filgotinib maleate
💬
| [10] IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TNF, TYK2 💬
| [97] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecule (CAM) interaction, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Efferocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Insulin resistance, Integrin signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Primary immunodeficiency, Prion disease, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 97 97 💬
|
| 359 | 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab | [4] Filgotinib Filgotinib, Infliximab, Ustekinumab, Vedolizumab | [5] Infliximab
Infliximab
,
Vedolizumab
,
Ustekinumab
,
Filgotinib
,
Filgotinib maleate
💬
| [10] IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TNF, TYK2 💬
| [97] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecule (CAM) interaction, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Efferocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Insulin resistance, Integrin signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Primary immunodeficiency, Prion disease, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 97 97 💬
|
| 360 | 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib | [4] Filgotinib Filgotinib, Infliximab, Ustekinumab, Vedolizumab | [5] Infliximab
Infliximab
,
Vedolizumab
,
Ustekinumab
,
Filgotinib
,
Filgotinib maleate
💬
| [10] IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TNF, TYK2 💬
| [97] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecule (CAM) interaction, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Efferocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Insulin resistance, Integrin signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Primary immunodeficiency, Prion disease, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 97 97 💬
|
| 361 | 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab | [4] Filgotinib Filgotinib, Infliximab, Ustekinumab, Vedolizumab | [5] Infliximab
Infliximab
,
Vedolizumab
,
Ustekinumab
,
Filgotinib
,
Filgotinib maleate
💬
| [10] IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TNF, TYK2 💬
| [97] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecule (CAM) interaction, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Efferocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Insulin resistance, Integrin signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Primary immunodeficiency, Prion disease, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 97 97 💬
|
| 362 | 1[(6- Allyl- 8beta- erg | - | - | - | - | [1] 6 6 💬
|
| 363 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | [1] 6 6 💬
|
| 364 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | [1] 6 6 💬
|
| 365 | 1[(6- Allyl- 8ß- erg | - | - | - | - | [1] 6 6 💬
|
| 366 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | [1] 6 6 💬
|
| 367 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | [1] 6 6 💬
|
| 368 | 1mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 369 | 1mg RPC1063 | - | - | - | - | [1] 96 96 💬
|
| 370 | 1mg/kg/hr TXA intravenous infusion till the last suture | - | - | - | - | [1] 70 70 💬
|
| 371 | 1mL prefilled syringes | - | - | - | - | [1] 107 107 💬
|
| 372 | 2 - Excipients | - | - | - | - | [1] 13 13 💬
|
| 373 | 2 infusions of MSC | - | - | - | - | [1] 51 51 💬
|
| 374 | 2 mA Transcranial Direct Current Stimulation | - | - | - | - | [1] 13 13 💬
|
| 375 | 2 mg perampanel | [1] Perampanel Perampanel | [2] Perampanel
Perampanel
,
Perampanel hydrate
💬
| [4] GRIA1 GRIA1, GRIA2, GRIA3, GRIA4 💬
| [17] Amphetamine addiction Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 376 | 2 million hMSC/kg | - | - | - | - | [1] 46 46 💬
|
| 377 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | [1] 97 97 💬
|
| 378 | 2% Chlorhexidine solution wipes | [1] Chlorhexidine Chlorhexidine | [4] Chlorhexidine gluconate
Chlorhexidine gluconate
,
Chlorhexidine hydrochloride
,
Chlorhexidine
,
Chlorhexidine acetate
💬
| - | - | [1] 299 299 💬
|
| 379 | 2% lignocaine | - | - | - | - | [1] 84 84 💬
|
| 380 | 2% sodium chondroitin sulfate | [1] Chondroitin sulfate Chondroitin sulfate | [1] Chondroitin sulfate A
Chondroitin sulfate A
💬
| - | - | [1] 226 226 💬
|
| 381 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | [1] Diflunisal Diflunisal | [1] Diflunisal
Diflunisal
💬
| [1] PTGS2 PTGS2 💬
| [22] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Efferocytosis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 28 28 💬
|
| 382 | 2'-Fucosyllactose | - | - | - | - | [2] 96 96, 97 💬
|
| 383 | 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA | - | - | - | - | [1] 113 113 💬
|
| 384 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING | [1] Ribose Ribose | - | - | - | [1] 131 131 💬
|
| 385 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID | [1] Ribose Ribose | - | - | - | [1] 131 131 💬
|
| 386 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | [1] 19 19 💬
|
| 387 | 2,3-dihydroxybutanedioic acid | - | - | - | - | [1] 299 299 💬
|
| 388 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | [1] 6 6 💬
|
| 389 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | [1] Benzoic acid Benzoic acid | [2] Benzoic acid
Benzoic acid
,
Sodium benzoate
💬
| - | - | [1] 51 51 💬
|
| 390 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | [1] Famciclovir Famciclovir | [1] Famciclovir
Famciclovir
💬
| - | - | [1] 13 13 💬
|
| 391 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | [1] 28 28 💬
|
| 392 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | [1] 28 28 💬
|
| 393 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | [1] 86 86 💬
|
| 394 | 2-[(E)-[(E)-3-[1-(2-nitrophenyl)pyrrol-2-yl]prop-2-enylidene]amino]guanidine | [1] Guanidine Guanidine | [1] Guanidine hydrochloride
Guanidine hydrochloride
💬
| - | - | [1] 46 46 💬
|
| 395 | 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydro-pyridazin-3-yloxy)- phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine-6-carbonitrile | - | - | - | - | [1] 79 79 💬
|
| 396 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | [2] 6 6, 162 💬
|
| 397 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | - | - | - | - | [1] 34 34 💬
|
| 398 | 2-aminoethanethiol | [1] Cysteamine Cysteamine | [3] Cysteamine
Cysteamine
,
Cysteamine hydrochloride
,
Cysteamine bitartrate
💬
| - | - | [1] 299 299 💬
|
| 399 | 2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 400 | 2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 401 | 2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 402 | 2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 403 | 2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 404 | 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 405 | 2-chloro-2'-deoxy-beta-D-adenosine (2-CdA) | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 406 | 2-chloro-2'-deoxy-ß-D-adenosine (2-CdA) | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 407 | 2-chloro-2'-deoxyadenosine (2-CdA) | [1] Cladribine Cladribine | [1] Cladribine
Cladribine
💬
| [1] RRM1 RRM1 💬
| [4] Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬 | [1] 13 13 💬
|
| 408 | 2-chloro-2'-deoxyadenosine, 2CdA | [1] Cladribine Cladribine | [1] Cladribine
Cladribine
💬
| [1] RRM1 RRM1 💬
| [4] Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬 | [1] 13 13 💬
|
| 409 | 2-chloro-2?-deoxy-beta-D-adenosine | [1] Adenosine Adenosine | [1] Adenosine
Adenosine
💬
| [4] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬
| [13] Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 410 | 2-chloro-2?-deoxy-ß-D-adenosine | [1] Adenosine Adenosine | [1] Adenosine
Adenosine
💬
| [4] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬
| [13] Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 411 | 2-chloro-2’-deoxy-beta-D-adenosine | [1] Adenosine Adenosine | [1] Adenosine
Adenosine
💬
| [4] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬
| [13] Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 412 | 2-chloro-2’-deoxy-beta-D-adenosine (2-CdA) | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 413 | 2-chloro-2’-deoxy-ß-D-adenosine | [1] Adenosine Adenosine | [1] Adenosine
Adenosine
💬
| [4] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬
| [13] Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 414 | 2-chloro-2’-deoxy-ß-D-adenosine (2-CdA) | [2] Adenosine Adenosine, Cladribine | [2] Adenosine
Adenosine
,
Cladribine
💬
| [5] ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬
| [17] Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 415 | 2-chloro-2’-deoxyadenosine (2-CdA) | [1] Cladribine Cladribine | [1] Cladribine
Cladribine
💬
| [1] RRM1 RRM1 💬
| [4] Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬 | [1] 13 13 💬
|
| 416 | 2-deoxy-2 [F-18] fluoro-2-d-glucose | [1] D-glucose D-glucose | [1] Glucose
Glucose
💬
| - | - | [1] 49 49 💬
|
| 417 | 2-HOBA | - | - | - | - | [2] 46 46, 86 💬
|
| 418 | 2-HOBA acetate (2-Hydroxybenzlamine acetate) | [1] Acetate Acetate | - | - | - | [1] 49 49 💬
|
| 419 | 2-hour Holter Monitor | - | - | - | - | [1] 19 19 💬
|
| 420 | 2-Hydroxybenzylamine | - | - | - | - | [1] 79 79 💬
|
| 421 | 2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione | [1] Imidazole Imidazole | - | - | - | [1] 21 21 💬
|
| 422 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | [1] Acetamide Acetamide | - | - | - | [1] 86 86 💬
|
| 423 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | - | - | - | - | [1] 46 46 💬
|
| 424 | 2-{[(8Z)-13-[(methylcarbamoyl)formamido]- tridec-8-en-1-yl]oxy}acetic acid | [1] Acetic acid Acetic acid | [1] Acetic acid, glacial
Acetic acid, glacial
💬
| - | - | [1] 21 21 💬
|
| 425 | 2-{[(8Z)-13-[(methylcarbamoyl)formamido]-tridec-8-en-1-yl]oxy}acetic acid | [1] Acetic acid Acetic acid | [1] Acetic acid, glacial
Acetic acid, glacial
💬
| - | - | [1] 21 21 💬
|
| 426 | 2.0 MIU IL-2 per day | - | - | - | - | [1] 2 2 💬
|
| 427 | 20 mg | - | - | - | - | [1] 97 97 💬
|
| 428 | 20 mg BID of PF-02545920 | - | - | - | - | [1] 8 8 💬
|
| 429 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | - | - | - | - | [1] 13 13 💬
|
| 430 | 20 mg GA | - | - | - | - | [1] 13 13 💬
|
| 431 | 20 mg MitoQ | - | - | - | - | [1] 13 13 💬
|
| 432 | 20 mg sildenafil citrate by mouth | [1] Sildenafil Sildenafil | [2] Sildenafil citrate
Sildenafil citrate
,
Sildenafil
💬
| [1] PDE5A PDE5A 💬
| [2] Purine metabolism Purine metabolism, cGMP-PKG signaling pathway 💬 | [1] 86 86 💬
|
| 433 | 20 mg/ml Treprostinil | [1] Treprostinil Treprostinil | [3] Treprostinil
Treprostinil
,
Treprostinil monosodium salt
,
Treprostinil diolamine
💬
| [1] PTGIR PTGIR 💬
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | [1] 86 86 💬
|
| 434 | 20 mL bupivacaine 0.25% injection | [1] Bupivacaine Bupivacaine | [2] Bupivacaine hydrochloride
Bupivacaine hydrochloride
,
Bupivacaine
💬
| [6] SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN8A, SCN9A 💬
| [5] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Cadherin signaling, Dopaminergic synapse, IgSF CAM signaling, Taste transduction 💬 | [1] 71 71 💬
|
| 435 | 20-valent pneumococcal conjugate vaccine | - | - | - | - | [1] 231 231 💬
|
| 436 | 200 mg BIA 6-512 | [1] BIA BIA | - | - | - | [1] 6 6 💬
|
| 437 | 200 mg FHND1002(fasting) | - | - | - | - | [1] 2 2 💬
|
| 438 | 200 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 439 | 200 mg/m2 dose | - | - | - | - | [1] 299 299 💬
|
| 440 | 200 µg Brimonidine Tartrate Implant | [1] Brimonidine Brimonidine | [2] Brimonidine tartrate
Brimonidine tartrate
,
Brimonidine
💬
| [3] ADRA2A ADRA2A, ADRA2B, ADRA2C 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | [1] 90 90 💬
|
| 441 | 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | - | - | - | - | [1] 235 235 💬
|
| 442 | 200106 or EMD 28162 | - | - | - | - | [1] 13 13 💬
|
| 443 | 200mg Cannabidiol by capsules twice daily | [1] Cannabidiol Cannabidiol | [1] Cannabidiol
Cannabidiol
💬
| [2] CNR1 CNR1, CNR2 💬
| [4] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | [1] 46 46 💬
|
| 444 | 200mg FHND1002(postprandial) | - | - | - | - | [1] 2 2 💬
|
| 445 | 2011-2012 seasonal flu vaccine Intramuscular | - | - | - | - | [2] 3 3, 113 💬
|
| 446 | 2011-2012 seasonal flu vaccine Subcutaneous | - | - | - | - | [2] 3 3, 113 💬
|
| 447 | 201600930 | - | - | - | - | [1] 2 2 💬
|
| 448 | 2019171-69-6 | - | - | - | - | [1] 61 61 💬
|
| 449 | 207-3120 | - | - | - | - | [1] 6 6 💬
|
| 450 | 20mg daily citalopram | [1] Citalopram Citalopram | [2] Citalopram hydrobromide
Citalopram hydrobromide
,
Citalopram
💬
| [1] SLC6A4 SLC6A4 💬
| [3] Neuroactive ligand signaling Neuroactive ligand signaling, Serotonergic synapse, Synaptic vesicle cycle 💬 | [1] 8 8 💬
|
| 451 | 20mg/0.5ml GA | - | - | - | - | [1] 13 13 💬
|
| 452 | 20mg/0.5ml glatiramer acetate | [2] Acetate Acetate, Glatiramer | [1] Glatiramer acetate
Glatiramer acetate
💬
| [20] HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬
| [32] Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagocytosis, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | [1] 13 13 💬
|
| 453 | 20mM sodium pyruvate nasal spray | [1] Pyruvic acid Pyruvic acid | - | - | - | [1] 85 85 💬
|
| 454 | 225mg SHP647 (PF-00547659) | - | - | - | - | [1] 97 97 💬
|
| 455 | 23-PPV | - | - | - | - | [1] 13 13 💬
|
| 456 | 23-valent pneumococcal polysaccharide vaccine | - | - | - | - | [3] 13 13, 46, 53 💬
|
| 457 | 23-valent pneumococcal polysaccharide vaccine (23-PPV) | - | - | - | - | [1] 13 13 💬
|
| 458 | 23-valent polysaccharide pneumococcal vaccine | - | - | - | - | [1] 96 96 💬
|
| 459 | 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM) | - | - | - | - | [2] 96 96, 97 💬
|
| 460 | 2387066 | - | - | - | - | [1] 56 56 💬
|
| 461 | 240mg Amantadine HCl ER tablets | [1] Amantadine Amantadine | [2] Amantadine hydrochloride
Amantadine hydrochloride
,
Amantadine
💬
| [5] GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬
| [21] Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 462 | 24mg bid TQH3906 capsule | - | - | - | - | [2] 96 96, 97 💬
|
| 463 | 25 mg BIA9 1067 | - | - | - | - | [1] 6 6 💬
|
| 464 | 25 mg Ongentys | - | - | - | - | [1] 6 6 💬
|
| 465 | 25 mg Ontamalimab | [1] Ontamalimab Ontamalimab | - | - | - | [2] 96 96, 97 💬
|
| 466 | 25% MTD sodium nitrite inhalation solution | [2] Nitrite Nitrite, Nitrous acid | [1] Sodium nitrite
Sodium nitrite
💬
| - | - | [1] 86 86 💬
|
| 467 | 25(OH)D3 | - | - | - | - | [1] 13 13 💬
|
| 468 | 250 mg CK-2017357 | - | - | - | - | [2] 2 2, 11 💬
|
| 469 | 250 mg LX3305 BID | - | - | - | - | [1] 46 46 💬
|
| 470 | 250 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 471 | 250mg FHND1002 | - | - | - | - | [1] 2 2 💬
|
| 472 | 250mg mesalazine pellets | [1] Mesalazine Mesalazine | [1] Mesalamine
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 473 | 25330 | - | - | - | - | [1] 6 6 💬
|
| 474 | 2593 | - | - | - | - | [1] 46 46 💬
|
| 475 | 25mcg rhPTH(1-84) | - | - | - | - | [1] 235 235 💬
|
| 476 | 25mg adalimumab-680LT and 15/25 mg risankizumab-800CW | [2] Adalimumab Adalimumab, Risankizumab | [2] Adalimumab
Adalimumab
,
Risankizumab
💬
| [2] IL23A IL23A, TNF 💬
| [69] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [2] 96 96, 97 💬
|
| 477 | 25OH-Vitamin D | [1] Vitamin D Vitamin D | - | - | - | [1] 13 13 💬
|
| 478 | 2622U90 Duramycin | - | - | - | - | [1] 299 299 💬
|
| 479 | 26866138 | - | - | - | - | [1] 28 28 💬
|
| 480 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | [1] 113 113 💬
|
| 481 | 291844 | - | - | - | - | [2] 246 246, 299 💬
|
| 482 | 2B3-201 | - | - | - | - | [1] 13 13 💬
|
| 483 | 2D and 3D trans-thoracic echocardiography | - | - | - | - | [2] 86 86, 88 💬
|
| 484 | 2D UC-MSC group | - | - | - | - | [1] 60 60 💬
|
| 485 | 2L polyethylene glycol/ascorbic acid | [2] Ascorbic acid Ascorbic acid, Polyethylene glycol | [4] Ascorbic acid
Ascorbic acid
,
Polyethylene glycol 3350
,
Macrogol 4000
,
Macrogol 6000
💬
| - | - | [1] 97 97 💬
|
| 486 | 2mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 487 | 2mg CS0159 | - | - | - | - | [1] 93 93 💬
|
| 488 | 2mg Overencapsulated Bumetanide | [1] Bumetanide Bumetanide | [1] Bumetanide
Bumetanide
💬
| [1] SLC12A2 SLC12A2 💬
| [3] Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | [1] 115 115 💬
|
| 489 | 2S,4R-(-)-ketoconazole | [1] Ketoconazole Ketoconazole | [1] Ketoconazole
Ketoconazole
💬
| - | - | [1] 75 75 💬
|
| 490 | 2S,4R-(-)-ketoconazole, levoketoconazole | [2] Ketoconazole Ketoconazole, Levoketoconazole | [2] Ketoconazole
Ketoconazole
,
Levoketoconazole
💬
| [3] CYP11A1 CYP11A1, CYP11B1, CYP17A1 💬
| [6] Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | [1] 75 75 💬
|
| 491 | 3 bottles of Lactulose oral solution | [1] Lactulose Lactulose | [1] Lactulose
Lactulose
💬
| - | - | [1] 97 97 💬
|
| 492 | 3 mg | - | - | - | - | [1] 299 299 💬
|
| 493 | 3 mg [14C]-A4250 capsule | - | - | - | - | [3] 93 93, 297, 338 💬
|
| 494 | 3 mg Melatonin | [1] Melatonin Melatonin | [1] Melatonin
Melatonin
💬
| [2] MTNR1A MTNR1A, MTNR1B 💬
| [2] Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | [1] 13 13 💬
|
| 495 | 3 mg QD to 15 mg QD PF-06649751 | - | - | - | - | [1] 6 6 💬
|
| 496 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | - | - | - | - | [1] 6 6 💬
|
| 497 | 3 mg tropicamide | [1] Tropicamide Tropicamide | [1] Tropicamide
Tropicamide
💬
| [5] CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬
| [14] Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 498 | 3 mg/kg GSK2402968 | - | - | - | - | [1] 113 113 💬
|
| 499 | 3 MPDN pulse + PDN | - | - | - | - | [1] 50 50 💬
|
| 500 | 3 MPDN pulse + PDN + CSA | - | - | - | - | [1] 50 50 💬
|
| 501 | 3 MPDN pulse + PDN + MTX | - | - | - | - | [1] 50 50 💬
|
| 502 | 3 Servings of broccoli sprouts | [1] Broccoli Broccoli | - | - | - | [1] 97 97 💬
|
| 503 | 3,4-DIAMINOPYRIDINE | - | - | - | - | [2] 12 12, 13 💬
|
| 504 | 3,4-Diaminopyridine Phosphate | - | - | - | - | [1] 3 3 💬
|
| 505 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | [1] 6 6 💬
|
| 506 | 3-(3,4-Dihydroxyphenyl)-L-alanine | [1] Alanine Alanine | [1] Alanine
Alanine
💬
| - | - | [1] 6 6 💬
|
| 507 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | [1] Acoramidis Acoramidis | [2] Acoramidis
Acoramidis
,
Acoramidis hydrochloride
💬
| [1] TTR TTR 💬
| [1] Thyroid hormone synthesis Thyroid hormone synthesis 💬 | [1] 28 28 💬
|
| 508 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | [1] 93 93 💬
|
| 509 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | [1] 93 93 💬
|
| 510 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | [2] 51 51, 85 💬
|
| 511 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | - | - | - | - | [2] 96 96, 97 💬
|
| 512 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | - | - | - | - | [1] 2 2 💬
|
| 513 | 3-N-butylphthalide | [1] Butylphthalide Butylphthalide | - | - | - | [1] 17 17 💬
|
| 514 | 30 or 60 mg | - | - | - | - | [1] 67 67 💬
|
| 515 | 30 or 90 mg | - | - | - | - | [1] 67 67 💬
|
| 516 | 30-hour ambulatory sampling of intestinal fluid | - | - | - | - | [1] 83 83 💬
|
| 517 | 300 mg double-blinded secukinumab | [1] Secukinumab Secukinumab | [1] Secukinumab
Secukinumab
💬
| [1] IL17A IL17A 💬
| [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 💬
|
| 518 | 300 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 519 | 300mg Gemcabene | [1] Gemcabene Gemcabene | - | - | - | [1] 265 265 💬
|
| 520 | 3108006977 | - | - | - | - | [1] 94 94 💬
|
| 521 | 320mg Amantadine HCl ER tablets | [1] Amantadine Amantadine | [2] Amantadine hydrochloride
Amantadine hydrochloride
,
Amantadine
💬
| [5] GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬
| [21] Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 522 | 32mg TQH3906 capsule | - | - | - | - | [2] 96 96, 97 💬
|
| 523 | 331731-18-1 | - | - | - | - | [4] 46 46, 96, 97, 271 💬
|
| 524 | 3400930060797 | - | - | - | - | [1] 36 36 💬
|
| 525 | 3400935113276 | - | - | - | - | [1] 56 56 💬
|
| 526 | 35565011 | - | - | - | - | [1] 46 46 💬
|
| 527 | 35mg | - | - | - | - | [2] 50 50, 107 💬
|
| 528 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | [1] Hyaluronidase Hyaluronidase | [3] Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬
| - | - | [1] 65 65 💬
|
| 529 | 39560 | - | - | - | - | [2] 96 96, 97 💬
|
| 530 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | [1] 93 93 💬
|
| 531 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | [1] 93 93 💬
|
| 532 | 3D hypoxia-preconditioned UC-MSC group | - | - | - | - | [1] 60 60 💬
|
| 533 | 3D-cultured human placental mesenchymal stem cell-derived extracellular vesicles | - | - | - | - | [1] 85 85 💬
|
| 534 | 3H-cholesterol bound to albumin | [1] Cholesterol Cholesterol | [1] Cholesterol
Cholesterol
💬
| - | - | [2] 259 259, 261 💬
|
| 535 | 3He Human Lung Coil | - | - | - | - | [1] 299 299 💬
|
| 536 | 3K3A-APC Protein | - | - | - | - | [1] 2 2 💬
|
| 537 | 3L-polyethylene glycol | [1] Polyethylene glycol Polyethylene glycol | [3] Polyethylene glycol 3350
Polyethylene glycol 3350
,
Macrogol 4000
,
Macrogol 6000
💬
| - | - | [1] 97 97 💬
|
| 538 | 4 cholesten-3-one, oxime | - | - | - | - | [1] 2 2 💬
|
| 539 | 4 mA Transcranial Direct Current Stimulation | - | - | - | - | [1] 13 13 💬
|
| 540 | 4 mg perampanel | [1] Perampanel Perampanel | [2] Perampanel
Perampanel
,
Perampanel hydrate
💬
| [4] GRIA1 GRIA1, GRIA2, GRIA3, GRIA4 💬
| [17] Amphetamine addiction Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 541 | 4 mg/kg CNTO 136 | - | - | - | - | [1] 49 49 💬
|
| 542 | 4 million hMSC/kg | - | - | - | - | [1] 46 46 💬
|
| 543 | 4% chlorhexidine gluconate liquid skin cleanser | [1] Chlorhexidine Chlorhexidine | [4] Chlorhexidine gluconate
Chlorhexidine gluconate
,
Chlorhexidine hydrochloride
,
Chlorhexidine
,
Chlorhexidine acetate
💬
| - | - | [1] 299 299 💬
|
| 544 | 4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulphonamide | - | - | - | - | [1] 46 46 💬
|
| 545 | 4'-iodo-4'-deoxydoxorubicin | - | - | - | - | [1] 28 28 💬
|
| 546 | 4,5-Dichloro-1,3-Benzenedisulphonamide | - | - | - | - | [1] 115 115 💬
|
| 547 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | [1] Methane Methane | - | - | - | [1] 2 2 💬
|
| 548 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | - | - | - | - | [1] 46 46 💬
|
| 549 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | - | - | - | - | [1] 46 46 💬
|
| 550 | 4-aminopyridine | - | - | - | - | [2] 3 3, 13 💬
|
| 551 | 4-Aminosalicylic acid | [1] Aminosalicylic acid Aminosalicylic acid | [1] Aminosalicylic acid
Aminosalicylic acid
💬
| - | - | [1] 96 96 💬
|
| 552 | 4-Aminosalicylic acid extended release granules | [1] Aminosalicylic acid Aminosalicylic acid | [1] Aminosalicylic acid
Aminosalicylic acid
💬
| - | - | [1] 96 96 💬
|
| 553 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | [1] 5 5 💬
|
| 554 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | [1] 113 113 💬
|
| 555 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | [1] 113 113 💬
|
| 556 | 4-cholesten-3-one, oxime | [1] Olesoxime Olesoxime | [1] Olesoxime
Olesoxime
💬
| - | - | [2] 2 2, 3 💬
|
| 557 | 4-cholesten-3-one,oxime | - | - | - | - | [1] 3 3 💬
|
| 558 | 4-Methylpyrazole | - | - | - | - | [1] 301 301 💬
|
| 559 | 4-PBA | - | - | - | - | [1] 231 231 💬
|
| 560 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | [1] 46 46 💬
|
| 561 | 4.2% NaCl | - | - | - | - | [1] 340 340 💬
|
| 562 | 4.2% NaCl/Inhalation solution | - | - | - | - | [2] 299 299, 340 💬
|
| 563 | 4.5 mg Naltrexone | [1] Naltrexone Naltrexone | [2] Naltrexone hydrochloride
Naltrexone hydrochloride
,
Naltrexone
💬
| [3] OPRD1 OPRD1, OPRK1, OPRM1 💬
| [7] Estrogen signaling pathway Estrogen signaling pathway, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 13 13 💬
|
| 564 | 40 mg | - | - | - | - | [1] 96 96 💬
|
| 565 | 40 mg GA | - | - | - | - | [2] 2 2, 13 💬
|
| 566 | 40 mg glatiramer acetate | [2] Acetate Acetate, Glatiramer | [1] Glatiramer acetate
Glatiramer acetate
💬
| [20] HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬
| [32] Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagocytosis, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | [2] 2 2, 13 💬
|
| 567 | 40 mg Glatiramer acetato | [1] Glatiramer Glatiramer | [1] Glatiramer acetate
Glatiramer acetate
💬
| [20] HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬
| [32] Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagocytosis, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | [1] 13 13 💬
|
| 568 | 40 mg MSB11022 | - | - | - | - | [5] 46 46, 96, 97, 107, 271 💬
|
| 569 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | [1] 107 107 💬
|
| 570 | 400 mg BIA 5-1058 | [1] BIA BIA | - | - | - | [1] 86 86 💬
|
| 571 | 400 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 572 | 400 µg Brimonidine Tartrate Implant | [1] Brimonidine Brimonidine | [2] Brimonidine tartrate
Brimonidine tartrate
,
Brimonidine
💬
| [3] ADRA2A ADRA2A, ADRA2B, ADRA2C 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | [1] 90 90 💬
|
| 573 | 400 µg of MBX 2109 once-weekly by subcutaneous injection | - | - | - | - | [1] 235 235 💬
|
| 574 | 400mg Cannabidiol by capsules twice daily | [1] Cannabidiol Cannabidiol | [1] Cannabidiol
Cannabidiol
💬
| [2] CNR1 CNR1, CNR2 💬
| [4] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | [1] 46 46 💬
|
| 575 | 40mg of MitoQ | - | - | - | - | [1] 13 13 💬
|
| 576 | 40mg Triamcinolone Injections in the Bladder | [1] Triamcinolone Triamcinolone | [4] Triamcinolone
Triamcinolone
,
Triamcinolone acetonide
,
Triamcinolone diacetate
,
Triamcinolone hexacetonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 226 226 💬
|
| 577 | 42942019 | - | - | - | - | [4] 46 46, 96, 97, 271 💬
|
| 578 | 436394 | - | - | - | - | [1] 288 288 💬
|
| 579 | 44/154/85-C | - | - | - | - | [1] 50 50 💬
|
| 580 | 44/196/81-C | - | - | - | - | [1] 50 50 💬
|
| 581 | 45 mg sodium nitrite inhalation solution | [2] Nitrite Nitrite, Nitrous acid | [1] Sodium nitrite
Sodium nitrite
💬
| - | - | [1] 86 86 💬
|
| 582 | 4AU76 | - | - | - | - | [1] 86 86 💬
|
| 583 | 4cc of lidocaïne® | - | - | - | - | [1] 149 149 💬
|
| 584 | 4D-125 IVT Injection | - | - | - | - | [1] 90 90 💬
|
| 585 | 4D-310 | [1] 4D-310 4D-310 | - | - | - | [1] 19 19 💬
|
| 586 | 4D-710 | - | - | - | - | [1] 299 299 💬
|
| 587 | 5 ASA, enemas, suppositories, corticosteroids | - | - | - | - | [1] 97 97 💬
|
| 588 | 5 mg Melatonin | [1] Melatonin Melatonin | [1] Melatonin
Melatonin
💬
| [2] MTNR1A MTNR1A, MTNR1B 💬
| [2] Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | [1] 13 13 💬
|
| 589 | 5 mg Montelukast | [1] Montelukast Montelukast | [2] Montelukast sodium
Montelukast sodium
,
Montelukast
💬
| [1] CYSLTR1 CYSLTR1 💬
| [2] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 590 | 5 mg Prednisone | [1] Prednisone Prednisone | [1] Prednisone
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 44 44 💬
|
| 591 | 5 x 10^6 UC-MSC + CM | - | - | - | - | [1] 90 90 💬
|
| 592 | 5% (5g/100 ml) intravenous immunoglobin | - | - | - | - | [1] 63 63 💬
|
| 593 | 5% Dextrose | - | - | - | - | [1] 57 57 💬
|
| 594 | 5% glucose water solution | [1] Water Water | [1] Water
Water
💬
| - | - | [1] 2 2 💬
|
| 595 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | [2] Estradiol Estradiol, Lidocaine | [5] Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride
,
Estradiol hemihydrate
,
Lidocaine hydrochloride monohydrate
💬
| [8] ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN8A, SCN9A 💬
| [15] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Cadherin signaling, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Estrogen signaling pathway, GnRH secretion, Hormone signaling, IgSF CAM signaling, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | [1] 226 226 💬
|
| 596 | 5% sildenafil cream | [1] Sildenafil Sildenafil | [2] Sildenafil citrate
Sildenafil citrate
,
Sildenafil
💬
| [1] PDE5A PDE5A 💬
| [2] Purine metabolism Purine metabolism, cGMP-PKG signaling pathway 💬 | [1] 50 50 💬
|
| 597 | 5% TolaSure Topical Gel | - | - | - | - | [1] 36 36 💬
|
| 598 | 5,6,7,8-tetrahydrobiopterin | - | - | - | - | [1] 240 240 💬
|
| 599 | 5,7-DICHLORO-2-((ETHYLAMINO)METHYL)-8-HYDROXY-3-METHYLQUINAZOLIN- | - | - | - | - | [1] 17 17 💬
|
| 600 | 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole | - | - | - | - | [1] 113 113 💬
|
| 601 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | - | - | - | - | [1] 20 20 💬
|
| 602 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | - | - | - | - | [1] 20 20 💬
|
| 603 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | - | - | - | - | [1] 20 20 💬
|
| 604 | 5-ALA (Gliolan) | - | - | - | - | [1] 137 137 💬
|
| 605 | 5-amino salicylic acid | [1] Salicylic acid Salicylic acid | [4] Salicylic acid
Salicylic acid
,
Sodium salicylate
,
Choline magnesium trisalicylate
,
Diethylamine salicylate
💬
| [2] PTGS1 PTGS1, PTGS2 💬
| [23] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Efferocytosis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 97 97 💬
|
| 606 | 5-amino salicylic acid (5-ASA) | [2] Mesalazine Mesalazine, Salicylic acid | [5] Salicylic acid
Salicylic acid
,
Mesalamine
,
Sodium salicylate
,
Choline magnesium trisalicylate
,
Diethylamine salicylate
💬
| [2] PTGS1 PTGS1, PTGS2 💬
| [23] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Efferocytosis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 97 97 💬
|
| 607 | 5-amino-2-hydroxybenzoic acid | - | - | - | - | [1] 97 97 💬
|
| 608 | 5-aminolevulinic acid | [1] Aminolevulinic acid Aminolevulinic acid | [2] Aminolevulinic acid hydrochloride
Aminolevulinic acid hydrochloride
,
Aminolevulinic acid
💬
| - | - | [1] 96 96 💬
|
| 609 | 5-Aminosalicyclic acid | - | - | - | - | [1] 97 97 💬
|
| 610 | 5-Aminosalicyl acid | - | - | - | - | [1] 96 96 💬
|
| 611 | 5-aminosalicylate (Pentasa, Ferring) | - | - | - | - | [2] 96 96, 97 💬
|
| 612 | 5-Aminosalicylic acid | [2] Aminosalicylic acid Aminosalicylic acid, Mesalazine | [2] Aminosalicylic acid
Aminosalicylic acid
,
Mesalamine
💬
| - | - | [2] 96 96, 97 💬
|
| 613 | 5-Aminosalicylic acid (5-ASA) | [2] Aminosalicylic acid Aminosalicylic acid, Mesalazine | [2] Aminosalicylic acid
Aminosalicylic acid
,
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 614 | 5-Aminosalicylic acid(5-ASA) and/or Prednisone | [2] Aminosalicylic acid Aminosalicylic acid, Prednisone | [2] Aminosalicylic acid
Aminosalicylic acid
,
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 97 97 💬
|
| 615 | 5-ASA | - | - | - | - | [1] 97 97 💬
|
| 616 | 5-ASA (5-Aminosalicylate) | - | - | - | - | [1] 97 97 💬
|
| 617 | 5-ASA MMx | [1] Mesalazine Mesalazine | [1] Mesalamine
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 618 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | - | - | - | - | [2] 46 46, 271 💬
|
| 619 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | [1] 8 8 💬
|
| 620 | 5-HTP | - | - | - | - | [2] 96 96, 97 💬
|
| 621 | 5-Hydroxytryptophan / Vitamin B6 | - | - | - | - | [1] 206 206 💬
|
| 622 | 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | - | - | - | - | [1] 228 228 💬
|
| 623 | 5-methyltetrahydrofolate and vitamin B12 | - | - | - | - | [1] 299 299 💬
|
| 624 | 5-MTHF | - | - | - | - | [1] 337 337 💬
|
| 625 | 5-probe cocktail | - | - | - | - | [1] 254 254 💬
|
| 626 | 5-year Follow-up DPA-714-PET/MRI | - | - | - | - | [1] 6 6 💬
|
| 627 | 50 mg | - | - | - | - | [1] 97 97 💬
|
| 628 | 50 mg AP1189 | - | - | - | - | [1] 46 46 💬
|
| 629 | 50 mg BIA 9 1067 | [1] BIA BIA | - | - | - | [1] 6 6 💬
|
| 630 | 50 mg ELX/25 mg TEZ/37.5 mg IVA | - | - | - | - | [1] 299 299 💬
|
| 631 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | [1] 299 299 💬
|
| 632 | 50 mg Etanercept | [1] Etanercept Etanercept | [1] Etanercept
Etanercept
💬
| [2] LTA LTA, TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 46 46 💬
|
| 633 | 50 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 634 | 50 mg Ongentys | - | - | - | - | [1] 6 6 💬
|
| 635 | 50 mg Usnoflast | [1] Usnoflast Usnoflast | [1] Usnoflast
Usnoflast
💬
| [1] NLRP3 NLRP3 💬
| [12] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Coronavirus disease, Cytosolic DNA-sensing pathway, Influenza A, Lipid and atherosclerosis, NOD-like receptor signaling pathway, Necroptosis, Pathogenic Escherichia coli infection, Pertussis, Salmonella infection, Shigellosis, Yersinia infection 💬 | [1] 2 2 💬
|
| 636 | 50 µg KIO-301 | [1] KIO-301 KIO-301 | - | - | - | [1] 90 90 💬
|
| 637 | 500 0500 0 | - | - | - | - | [1] 19 19 💬
|
| 638 | 500 mg CK-2017357 | - | - | - | - | [2] 2 2, 11 💬
|
| 639 | 500 mg LX3305 QD | - | - | - | - | [1] 46 46 💬
|
| 640 | 5000 IU D3 | - | - | - | - | [1] 96 96 💬
|
| 641 | 5000 IU of cholecalciferol | [1] Cholecalciferol Cholecalciferol | [1] Cholecalciferol
Cholecalciferol
💬
| [1] VDR VDR 💬
| [5] Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | [1] 299 299 💬
|
| 642 | 5000IU vitamin D | [1] Vitamin D Vitamin D | - | - | - | [1] 13 13 💬
|
| 643 | 5009111000001105 | - | - | - | - | [1] 43 43 💬
|
| 644 | 500mg mesalazine pellets | [1] Mesalazine Mesalazine | [1] Mesalamine
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 645 | 500mg RTX Group | - | - | - | - | [1] 46 46 💬
|
| 646 | 5057732 | - | - | - | - | [1] 271 271 💬
|
| 647 | 5081 | - | - | - | - | [1] 90 90 💬
|
| 648 | 50mcg rhPTH(1-84) | - | - | - | - | [1] 235 235 💬
|
| 649 | 50mg FHND1002 | - | - | - | - | [1] 2 2 💬
|
| 650 | 52069.00.01 | - | - | - | - | [1] 13 13 💬
|
| 651 | 534-1508 | - | - | - | - | [1] 85 85 💬
|
| 652 | 549-0261/F02-01 | - | - | - | - | [2] 96 96, 97 💬
|
| 653 | 552-02 | - | - | - | - | [2] 53 53, 299 💬
|
| 654 | 56/104/75-C | - | - | - | - | [1] 50 50 💬
|
| 655 | 5mg | - | - | - | - | [2] 50 50, 107 💬
|
| 656 | 5mg lenalidomide | [1] Lenalidomide Lenalidomide | [1] Lenalidomide
Lenalidomide
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 300 300 💬
|
| 657 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | [1] 93 93 💬
|
| 658 | 6 Mercaptopurine | [1] Mercaptopurine Mercaptopurine | [2] Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬
| [1] HPRT1 HPRT1 💬
| [2] Drug metabolism - other enzymes Drug metabolism - other enzymes, Purine metabolism 💬 | [2] 96 96, 97 💬
|
| 659 | 6 mg/kg GSK2402968 | - | - | - | - | [1] 113 113 💬
|
| 660 | 6 million hMSC/kg | - | - | - | - | [1] 46 46 💬
|
| 661 | 6% Hypertonic Saline (HS), 4mL | - | - | - | - | [1] 299 299 💬
|
| 662 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | [1] 38 38 💬
|
| 663 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | [1] 46 46 💬
|
| 664 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | [1] 96 96 💬
|
| 665 | 6-[18F]Fluorodopa | - | - | - | - | [1] 6 6 💬
|
| 666 | 6-[18F]Fluorodopamine | - | - | - | - | [1] 6 6 💬
|
| 667 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | [1] 97 97 💬
|
| 668 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | [1] 2 2 💬
|
| 669 | 6-Mercaptopurine | [1] Mercaptopurine Mercaptopurine | [2] Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬
| [1] HPRT1 HPRT1 💬
| [2] Drug metabolism - other enzymes Drug metabolism - other enzymes, Purine metabolism 💬 | [3] 96 96, 97, 164 💬
|
| 670 | 6-Mercaptopurine (Puri-Nethol) | [1] Mercaptopurine Mercaptopurine | [2] Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬
| [1] HPRT1 HPRT1 💬
| [2] Drug metabolism - other enzymes Drug metabolism - other enzymes, Purine metabolism 💬 | [1] 96 96 💬
|
| 671 | 600mg Gemcabene | [1] Gemcabene Gemcabene | - | - | - | [1] 265 265 💬
|
| 672 | 608 dose | - | - | - | - | [1] 271 271 💬
|
| 673 | 608 Dose A | - | - | - | - | [1] 271 271 💬
|
| 674 | 608 Dose B | - | - | - | - | [1] 271 271 💬
|
| 675 | 608 Dose C | - | - | - | - | [1] 271 271 💬
|
| 676 | 626 | - | - | - | - | [1] 49 49 💬
|
| 677 | 627 | - | - | - | - | [1] 97 97 💬
|
| 678 | 64CuCl2 | - | - | - | - | [1] 171 171 💬
|
| 679 | 66215-101 | - | - | - | - | [1] 86 86 💬
|
| 680 | 68125 | - | - | - | - | [2] 96 96, 97 💬
|
| 681 | 683699 | - | - | - | - | [1] 96 96 💬
|
| 682 | 68Ga-BMV101 | - | - | - | - | [1] 85 85 💬
|
| 683 | 68Ga-BNOTA-PRGD2 | - | - | - | - | [1] 46 46 💬
|
| 684 | 68Ga-DOTA-TATE PET/MR and PET/CT imaging | - | - | - | - | [1] 238 238 💬
|
| 685 | 68Ga-DOTANOC | - | - | - | - | [1] 84 84 💬
|
| 686 | 68Ga-DOTATATE | [1] Dotatate Dotatate | - | - | - | [1] 75 75 💬
|
| 687 | 68Ga-DOTATATE PET/CT | [1] Dotatate Dotatate | - | - | - | [1] 84 84 💬
|
| 688 | 68Ga-FAPI | - | - | - | - | [4] 46 46, 53, 97, 300 💬
|
| 689 | 68Ga-NEB | - | - | - | - | [4] 46 46, 89, 278, 280 💬
|
| 690 | 68Ga-P16-093 | - | - | - | - | [1] 53 53 💬
|
| 691 | 68Ga-Pentixafor | - | - | - | - | [1] 75 75 💬
|
| 692 | 68GaNOTA-Anti-MMR-VHH2 | - | - | - | - | [1] 84 84 💬
|
| 693 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 694 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 695 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid | - | - | - | - | [1] 93 93 💬
|
| 696 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 697 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 698 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 699 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 700 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid | - | - | - | - | [1] 93 93 💬
|
| 701 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 702 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 703 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 704 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | [1] Obeticholic acid Obeticholic acid | [1] Obeticholic acid
Obeticholic acid
💬
| [1] NR1H4 NR1H4 💬
| [1] Bile secretion Bile secretion 💬 | [1] 93 93 💬
|
| 705 | 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate | [1] Apomorphine Apomorphine | [2] Apomorphine hydrochloride
Apomorphine hydrochloride
,
Apomorphine
💬
| [2] DRD1 DRD1, DRD2 💬
| [13] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 706 | 6aß - apomorphine-10,11-diol hydrochloride hemihydrate | [1] Apomorphine Apomorphine | [2] Apomorphine hydrochloride
Apomorphine hydrochloride
,
Apomorphine
💬
| [2] DRD1 DRD1, DRD2 💬
| [13] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | [1] 6 6 💬
|
| 707 | 6R-BH4 | [1] Sapropterin Sapropterin | [2] Sapropterin dihydrochloride
Sapropterin dihydrochloride
,
Sapropterin
💬
| - | - | [1] 124 124 💬
|
| 708 | 7 mg QD to 15 mg QD PF-06649751 | - | - | - | - | [1] 6 6 💬
|
| 709 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | - | - | - | - | [1] 6 6 💬
|
| 710 | 7% Hypertonic Saline (HS) | - | - | - | - | [1] 299 299 💬
|
| 711 | 7% Hypertonic Saline via nebulization | - | - | - | - | [1] 299 299 💬
|
| 712 | 7% NaCl | - | - | - | - | [1] 299 299 💬
|
| 713 | 7% saline | - | - | - | - | [1] 299 299 💬
|
| 714 | 7-beta-Hydroxyepiandrosterone | [1] 7-beta-Hydroxyepiandrosterone 7-beta-Hydroxyepiandrosterone | - | - | - | [1] 6 6 💬
|
| 715 | 7-day Fasting-Mimicking Diet (7-DAY FMD) | - | - | - | - | [1] 13 13 💬
|
| 716 | 7-valent Pneumococcal Conjugate vaccine | - | - | - | - | [2] 46 46, 222 💬
|
| 717 | 70930.00.00 | - | - | - | - | [1] 46 46 💬
|
| 718 | 75 | - | - | - | - | [1] 6 6 💬
|
| 719 | 75 mg Ontamalimab | [1] Ontamalimab Ontamalimab | - | - | - | [2] 96 96, 97 💬
|
| 720 | 75 mg Usnoflast | [1] Usnoflast Usnoflast | [1] Usnoflast
Usnoflast
💬
| [1] NLRP3 NLRP3 💬
| [12] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Coronavirus disease, Cytosolic DNA-sensing pathway, Influenza A, Lipid and atherosclerosis, NOD-like receptor signaling pathway, Necroptosis, Pathogenic Escherichia coli infection, Pertussis, Salmonella infection, Shigellosis, Yersinia infection 💬 | [1] 2 2 💬
|
| 721 | 75-mg IVACAFTOR | [1] Ivacaftor Ivacaftor | [1] Ivacaftor
Ivacaftor
💬
| [1] CFTR CFTR 💬
| [9] ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Phagocytosis, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | [1] 299 299 💬
|
| 722 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | [2] Citrulline Citrulline, Metformin | [4] Metformin hydrochloride
Metformin hydrochloride
,
Metformin
,
L-Citrulline
,
Citrulline malate
💬
| [2] PRKAA1 PRKAA1, PRKAA2 💬
| [20] AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | [1] 113 113 💬
|
| 723 | 750mg mesalazine pellets | [1] Mesalazine Mesalazine | [1] Mesalamine
Mesalamine
💬
| - | - | [1] 97 97 💬
|
| 724 | 755nm Alexandrite Laser | - | - | - | - | [1] 34 34 💬
|
| 725 | 75mg CXA-10 | [1] CXA-10 CXA-10 | - | - | - | [1] 86 86 💬
|
| 726 | 75mg SHP647 (PF-00547659) | - | - | - | - | [1] 97 97 💬
|
| 727 | 76517-01-4 | - | - | - | - | [1] 77 77 💬
|
| 728 | 80 mg DR-6MP | - | - | - | - | [1] 96 96 💬
|
| 729 | 800 mg ibuprofen/26.6 mg famotidine | [2] Famotidine Famotidine, Ibuprofen | [6] Ibuprofen
Ibuprofen
,
Famotidine
,
Ibuprofen aluminum
,
Ibuprofen lysine
,
Ibuprofen sodium
,
Ibuprofen sodium
💬
| [3] HRH2 HRH2, PTGS1, PTGS2 💬
| [27] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Efferocytosis, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 107 107 💬
|
| 730 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | [1] 299 299 💬
|
| 731 | 81409-90-7 | - | - | - | - | [1] 77 77 💬
|
| 732 | 81mg aspirin | - | - | - | - | [1] 49 49 💬
|
| 733 | 8594739041288 | - | - | - | - | [1] 46 46 💬
|
| 734 | 8699505952864 | - | - | - | - | [1] 56 56 💬
|
| 735 | 89 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled) | - | - | - | - | [1] 19 19 💬
|
| 736 | 89 Zr-Df-crefmirlimab | [1] Crefmirlimab Crefmirlimab | - | - | - | [2] 13 13, 25 💬
|
| 737 | 89Zr-bevacizumab | [2] Bevacizumab Bevacizumab, Bevacizumab zirconium Zr-89 | [1] Bevacizumab
Bevacizumab
💬
| [1] VEGFA VEGFA 💬
| [24] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Integrin signaling, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | [1] 34 34 💬
|
| 738 | 89Zr-DFO-AP-101 | [1] AP-101 AP-101 | - | - | - | [1] 2 2 💬
|
| 739 | 89Zr-DFO-CZP | - | - | - | - | [1] 46 46 💬
|
| 740 | 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb) | - | - | - | - | [1] 28 28 💬
|
| 741 | 89Zr-SBC-103 | - | - | - | - | [1] 19 19 💬
|
| 742 | 9 mg/kg GSK2402968 | - | - | - | - | [1] 113 113 💬
|
| 743 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | [1] 46 46 💬
|
| 744 | 9-cis beta-Carotene-rich extract of Dunaliella alga | - | - | - | - | [1] 90 90 💬
|
| 745 | 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | [1] Linoleic acid Linoleic acid | - | - | - | [2] 2 2, 5 💬
|
| 746 | 90 mg hydrocortisone acetate suppository with Sephure suppository applicator | [3] Acetate Acetate, Hydrocortisone, Hydrocortisone acetate | [2] Hydrocortisone
Hydrocortisone
,
Hydrocortisone acetate
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 97 97 💬
|
| 747 | 90 mg idrocortisone acetato in supposta con applicatore per supposte Sephure | - | - | - | - | [1] 97 97 💬
|
| 748 | 90 mg sodium nitrite inhalation solution | [2] Nitrite Nitrite, Nitrous acid | [1] Sodium nitrite
Sodium nitrite
💬
| - | - | [1] 86 86 💬
|
| 749 | 900mg TETA 4HCl Cuprior® | - | - | - | - | [1] 171 171 💬
|
| 750 | 900mg TETA 4HCl Once Daily Formulation | - | - | - | - | [1] 171 171 💬
|
| 751 | 9060X | - | - | - | - | [2] 13 13, 149 💬
|
| 752 | 95% Pure ECGC capsules 200mg | - | - | - | - | [1] 13 13 💬
|
| 753 | 9512 | - | - | - | - | [1] 46 46 💬
|
| 754 | 9715X | - | - | - | - | [1] 90 90 💬
|
| 755 | 9741X | - | - | - | - | [1] 90 90 💬
|
| 756 | 9742X | - | - | - | - | [1] 90 90 💬
|
| 757 | 98% dehydrated alcohol | - | - | - | - | [1] 298 298 💬
|
| 758 | 98-92-0 | - | - | - | - | [1] 107 107 💬
|
| 759 | 99m technetium infliximab | [1] Infliximab Infliximab | [1] Infliximab
Infliximab
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 84 84 💬
|
| 760 | 99mTc-3PRGD2 | - | - | - | - | [1] 46 46 💬
|
| 761 | 99mTc-Infliximab | [1] Infliximab Infliximab | [1] Infliximab
Infliximab
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 84 84 💬
|
| 762 | 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg | - | - | - | - | [1] 46 46 💬
|
| 763 | 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m. | - | - | - | - | [1] 28 28 💬
|
| 764 | 99mTc-PYP | - | - | - | - | [1] 28 28 💬
|
| 765 | 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m. | - | - | - | - | [1] 28 28 💬
|
| 766 | 99mTc-rhAnnexin V-128 | - | - | - | - | [2] 46 46, 271 💬
|
| 767 | 99mTc-S-HYNIC Certolizumab pegol | [1] Certolizumab pegol Certolizumab pegol | [1] Certolizumab pegol
Certolizumab pegol
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [2] 46 46, 96 💬
|
| 768 | 9MW3811 Injection | - | - | - | - | [1] 85 85 💬
|
| 769 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | [1] 86 86 💬
|
| 770 | : [R-(R*, R*)]-2-(4-fluorophenyl)-beta, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbony | - | - | - | - | [1] 79 79 💬
|
| 771 | : [R-(R*, R*)]-2-(4-fluorophenyl)-ß, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbony | - | - | - | - | [1] 79 79 💬
|
| 772 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | [1] 14 14 💬
|
| 773 | Aspaveli | - | - | - | - | [1] 223 223 💬
|
| 774 | ?-3 polyunsaturated fatty acid | - | - | - | - | [1] 96 96 💬
|
| 775 | [ 18F]3F4AP | - | - | - | - | [1] 13 13 💬
|
| 776 | [ ISIS 396443, BIIB058] | - | - | - | - | [1] 3 3 💬
|
| 777 | [ PTC923] | - | - | - | - | [1] 240 240 💬
|
| 778 | [000000000] | - | - | - | - | [1] 66 66 💬
|
| 779 | [0000] | - | - | - | - | [1] 3 3 💬
|
| 780 | [015628086] | - | - | - | - | [1] 49 49 💬
|
| 781 | [023145028] | - | - | - | - | [1] 6 6 💬
|
| 782 | [024217034] | - | - | - | - | [1] 1 1 💬
|
| 783 | [032166011] | - | - | - | - | [1] 13 13 💬
|
| 784 | [033283045] | - | - | - | - | [1] 13 13 💬
|
| 785 | [034091165] | - | - | - | - | [1] 13 13 💬
|
| 786 | [035418060] | - | - | - | - | [1] 13 13 💬
|
| 787 | [041381029] | - | - | - | - | [1] 48 48 💬
|
| 788 | [043906039] | - | - | - | - | [1] 6 6 💬
|
| 789 | [045251016] | - | - | - | - | [1] 19 19 💬
|
| 790 | [045450032] | - | - | - | - | [1] 49 49 💬
|
| 791 | [045833011] | - | - | - | - | [1] 49 49 💬
|
| 792 | [0C23] | - | - | - | - | [1] 67 67 💬
|
| 793 | [11C]-CS1P1 | - | - | - | - | [1] 6 6 💬
|
| 794 | [11C]-GSK2256098 500 MBq | [1] GSK2256098 GSK2256098 | - | - | - | [1] 86 86 💬
|
| 795 | [11C]-methionine | [1] Methionine Methionine | [1] Methionine
Methionine
💬
| - | - | [1] 34 34 💬
|
| 796 | [11C]-PIB | - | - | - | - | [1] 6 6 💬
|
| 797 | [11C]-PK-11195 | - | - | - | - | [1] 13 13 💬
|
| 798 | [11C]acetate | [1] Acetate Acetate | - | - | - | [2] 89 89, 158 💬
|
| 799 | [11C]AZ14132516 | - | - | - | - | [1] 96 96 💬
|
| 800 | [11C]CPPC Injection | - | - | - | - | [1] 2 2 💬
|
| 801 | [11C]flumazenil | [1] Flumazenil Flumazenil | [1] Flumazenil
Flumazenil
💬
| [16] GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬
| [9] Cadherin signaling Cadherin signaling, GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | [1] 13 13 💬
|
| 802 | [11C]MODAG-005 | - | - | - | - | [2] 6 6, 17 💬
|
| 803 | [11C]MPC6827 | - | - | - | - | [1] 2 2 💬
|
| 804 | [11C]PBR28 | - | - | - | - | [1] 6 6 💬
|
| 805 | [11C]PIB | - | - | - | - | [1] 13 13 💬
|
| 806 | [11C]PXT012253 | - | - | - | - | [1] 6 6 💬
|
| 807 | [11C]SMW139 | - | - | - | - | [1] 6 6 💬
|
| 808 | [123I] 5-IA | - | - | - | - | [1] 6 6 💬
|
| 809 | [123I] IBVM and SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 810 | [123I] mZINT injection and serial dynamic SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 811 | [123I]-IBVM | - | - | - | - | [1] 6 6 💬
|
| 812 | [123I]-IBZM imaging | - | - | - | - | [1] 6 6 💬
|
| 813 | [123I]B-CIT | - | - | - | - | [1] 6 6 💬
|
| 814 | [123I]B-CIT SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 815 | [123I]beta CIT | - | - | - | - | [1] 6 6 💬
|
| 816 | [123I]beta CIT and SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 817 | [123I]beta-CIT | - | - | - | - | [1] 6 6 💬
|
| 818 | [123I]beta-CIT and SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 819 | [123I]CLINDE | - | - | - | - | [2] 6 6, 13 💬
|
| 820 | [123I]MNI-420 | - | - | - | - | [2] 6 6, 8 💬
|
| 821 | [123I]ß CIT | - | - | - | - | [1] 6 6 💬
|
| 822 | [123I]ß CIT and SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 823 | [123I]ß-CIT | - | - | - | - | [1] 6 6 💬
|
| 824 | [123I]ß-CIT and SPECT imaging | - | - | - | - | [1] 6 6 💬
|
| 825 | [124I]IB PF 06687234 | - | - | - | - | [2] 96 96, 97 💬
|
| 826 | [14C] AT1001 | - | - | - | - | [1] 19 19 💬
|
| 827 | [14C] LPM3770164 | - | - | - | - | [1] 8 8 💬
|
| 828 | [14C]-BIA 9-1067 | [1] BIA BIA | - | - | - | [1] 6 6 💬
|
| 829 | [14C]-Genz-112638 | - | - | - | - | [1] 19 19 💬
|
| 830 | [14C]-ONO-5788 | - | - | - | - | [1] 77 77 💬
|
| 831 | [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | [3] 13 13, 96, 97 💬
|
| 832 | [14C]CS0159 | - | - | - | - | [1] 93 93 💬
|
| 833 | [14C]JMKX003142 | - | - | - | - | [1] 67 67 💬
|
| 834 | [14C]JMKX003142 solution for infusion | - | - | - | - | [1] 67 67 💬
|
| 835 | [15-O]water | [1] Water Water | [1] Water
Water
💬
| - | - | [1] 206 206 💬
|
| 836 | [15O]H2O | - | - | - | - | [1] 6 6 💬
|
| 837 | [18-F]DPA-714 | - | - | - | - | [1] 127 127 💬
|
| 838 | [18683-91-5] | - | - | - | - | [1] 6 6 💬
|
| 839 | [18F] APN-1607 | - | - | - | - | [1] 5 5 💬
|
| 840 | [18F] AV-133 PET Imaging | - | - | - | - | [1] 6 6 💬
|
| 841 | [18F] CFPyPB | - | - | - | - | [1] 6 6 💬
|
| 842 | [18F] FES | - | - | - | - | [1] 86 86 💬
|
| 843 | [18F] FZTA | - | - | - | - | [1] 13 13 💬
|
| 844 | [18F] GE-180 | - | - | - | - | [1] 2 2 💬
|
| 845 | [18F] LBT-999 | - | - | - | - | [1] 6 6 💬
|
| 846 | [18F] LBT-999 PET | - | - | - | - | [1] 6 6 💬
|
| 847 | [18F] PBR06 | - | - | - | - | [2] 6 6, 13 💬
|
| 848 | [18F] PI-2620 | - | - | - | - | [1] 6 6 💬
|
| 849 | [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | [1] 6 6 💬
|
| 850 | [18F]-FAPI-74 | - | - | - | - | [1] 50 50 💬
|
| 851 | [18F]-FBA-A20FMDV2 | - | - | - | - | [1] 85 85 💬
|
| 852 | [18F]-FEPPA | - | - | - | - | [2] 6 6, 13 💬
|
| 853 | [18F]-FLT-PET/CT scans | - | - | - | - | [1] 34 34 💬
|
| 854 | [18F]-MNI-659 | - | - | - | - | [1] 8 8 💬
|
| 855 | [18F]-PI-2620 | - | - | - | - | [1] 127 127 💬
|
| 856 | [18F]-PI2620 | - | - | - | - | [1] 5 5 💬
|
| 857 | [18F]ABBV-964i | - | - | - | - | [1] 5 5 💬
|
| 858 | [18F]ABBV-965i | - | - | - | - | [1] 5 5 💬
|
| 859 | [18F]DPA-714 | - | - | - | - | [2] 13 13, 127 💬
|
| 860 | [18F]DPA-714 PET | - | - | - | - | [1] 2 2 💬
|
| 861 | [18F]DPA-714 PET scan | - | - | - | - | [1] 6 6 💬
|
| 862 | [18F]FAPI-74 | - | - | - | - | [1] 86 86 💬
|
| 863 | [18F]FDOPA | - | - | - | - | [2] 6 6, 17 💬
|
| 864 | [18F]FDOPA PET/CT | - | - | - | - | [1] 6 6 💬
|
| 865 | [18F]FE-PE2I | - | - | - | - | [1] 6 6 💬
|
| 866 | [18F]Florbetaben | - | - | - | - | [1] 28 28 💬
|
| 867 | [18F]Florbetapir | - | - | - | - | [1] 5 5 💬
|
| 868 | [18F]Florbetapir PET imaging | - | - | - | - | [1] 13 13 💬
|
| 869 | [18F]flumazenil | [1] Flumazenil Flumazenil | [1] Flumazenil
Flumazenil
💬
| [16] GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬
| [9] Cadherin signaling Cadherin signaling, GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | [1] 206 206 💬
|
| 870 | [18F]Fluoride | - | - | - | - | [1] 271 271 💬
|
| 871 | [18F]Fluoro-2-deoxy-2-D-glucose | [1] D-glucose D-glucose | [1] Glucose
Glucose
💬
| - | - | [2] 86 86, 88 💬
|
| 872 | [18F]FP-R01-MG-F2 | - | - | - | - | [2] 85 85, 94 💬
|
| 873 | [18F]FPEB | - | - | - | - | [3] 6 6, 8, 206 💬
|
| 874 | [18F]FPEB PET imaging | - | - | - | - | [1] 206 206 💬
|
| 875 | [18F]FSPG | - | - | - | - | [2] 96 96, 97 💬
|
| 876 | [18F]MC225 | - | - | - | - | [1] 6 6 💬
|
| 877 | [18F]MK-0947 | - | - | - | - | [1] 6 6 💬
|
| 878 | [18F]MK-9470 | - | - | - | - | [1] 6 6 💬
|
| 879 | [18F]MK6240 | - | - | - | - | [1] 13 13 💬
|
| 880 | [18F]MNI-1126 | - | - | - | - | [1] 6 6 💬
|
| 881 | [18F]MNI-1216 | - | - | - | - | [1] 6 6 💬
|
| 882 | [18F]MNI-815 (MNI-815) | - | - | - | - | [1] 5 5 💬
|
| 883 | [18F]MNI-952 | - | - | - | - | [1] 5 5 💬
|
| 884 | [18F]MNI-958 | - | - | - | - | [1] 5 5 💬
|
| 885 | [18F]MPPF | - | - | - | - | [1] 6 6 💬
|
| 886 | [18F]NOS | - | - | - | - | [1] 6 6 💬
|
| 887 | [18F]P17-059 | - | - | - | - | [1] 6 6 💬
|
| 888 | [18F]PBR06 | - | - | - | - | [1] 2 2 💬
|
| 889 | [18F]PEG-Folate | - | - | - | - | [2] 41 41, 46 💬
|
| 890 | [18F]PI-2620 | - | - | - | - | [2] 6 6, 127 💬
|
| 891 | [18F]RP-115 PET/MRI or PET/CT and MRI | - | - | - | - | [1] 127 127 💬
|
| 892 | [18F]T807 ([18F]MNI-777) | - | - | - | - | [2] 5 5, 6 💬
|
| 893 | [18F]UCB-2897 | - | - | - | - | [1] 6 6 💬
|
| 894 | [18F]UCB-H | - | - | - | - | [1] 13 13 💬
|
| 895 | [2019171-69-6] | - | - | - | - | [1] 61 61 💬
|
| 896 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | [1] 6 6 💬
|
| 897 | [6036937.00.01] | - | - | - | - | [1] 6 6 💬
|
| 898 | [64Cu]Cl2 | - | - | - | - | [1] 171 171 💬
|
| 899 | [68Ga]CBP8 | - | - | - | - | [1] 85 85 💬
|
| 900 | [68Ga]Ga-DOTA-Cys-ATH001 | - | - | - | - | [1] 96 96 💬
|
| 901 | [68Ga]Ga-PentixaFor PET/CT | - | - | - | - | [1] 84 84 💬
|
| 902 | [89Zr]Zr-Df-crefmirlimab berdoxam | [1] Crefmirlimab Crefmirlimab | - | - | - | [2] 51 51, 53 💬
|
| 903 | [90 mg idrocortisone acetato in supposta con appli | - | - | - | - | [1] 97 97 💬
|
| 904 | [A042917017] | - | - | - | - | [1] 21 21 💬
|
| 905 | [A16AB04] | - | - | - | - | [1] 19 19 💬
|
| 906 | [A4250] | - | - | - | - | [3] 296 296, 297, 338 💬
|
| 907 | [AAV2/8.TBG.hARSB] | - | - | - | - | [1] 19 19 💬
|
| 908 | [AB1010] | - | - | - | - | [2] 2 2, 13 💬
|
| 909 | [Abalimumab bio-originatore] | - | - | - | - | [1] 107 107 💬
|
| 910 | [Abatacept] | [1] Abatacept Abatacept | [1] Abatacept
Abatacept
💬
| [2] CD80 CD80, CD86 💬
| [14] Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Graft-versus-host disease, IgSF CAM signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | [1] 300 300 💬
|
| 911 | [ABBV-006] | - | - | - | - | [1] 97 97 💬
|
| 912 | [ABBV-066] | - | - | - | - | [2] 96 96, 97 💬
|
| 913 | [ABBV-105] | - | - | - | - | [1] 49 49 💬
|
| 914 | [ABBV-154] | - | - | - | - | [2] 46 46, 96 💬
|
| 915 | [ABBV-323] | - | - | - | - | [1] 97 97 💬
|
| 916 | [ABBV-951] | - | - | - | - | [1] 6 6 💬
|
| 917 | [ABT-494] | - | - | - | - | [7] 41 41, 46, 49, 96, 97, 107, 271 💬
|
| 918 | [ABX464] | - | - | - | - | [1] 97 97 💬
|
| 919 | [ACE-011] | - | - | - | - | [1] 86 86 💬
|
| 920 | [ACE-1334] | - | - | - | - | [1] 51 51 💬
|
| 921 | [ACE-536] | - | - | - | - | [1] 282 282 💬
|
| 922 | [Acetazolamide] | [1] Acetazolamide Acetazolamide | [2] Acetazolamide
Acetazolamide
,
Acetazolamide sodium
💬
| [13] CA1 CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 💬
| [6] Bile secretion Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation 💬 | [1] 230 230 💬
|
| 923 | [acetominofene] | - | - | - | - | [2] 11 11, 63 💬
|
| 924 | [ACH-0144471] | [1] Danicopan Danicopan | [1] Danicopan
Danicopan
💬
| [1] CFD CFD 💬
| [3] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, Staphylococcus aureus infection 💬 | [1] 62 62 💬
|
| 925 | [ACT-064992] | - | - | - | - | [1] 86 86 💬
|
| 926 | [ACT-293987 / JNJ-67896049] | - | - | - | - | [1] 84 84 💬
|
| 927 | [ACT-293987] | - | - | - | - | [1] 88 88 💬
|
| 928 | [ACT-334441] | - | - | - | - | [1] 49 49 💬
|
| 929 | [ACT-434964] | - | - | - | - | [1] 19 19 💬
|
| 930 | [ACT-HIB] | - | - | - | - | [2] 62 62, 223 💬
|
| 931 | [ACU-4429] | - | - | - | - | [1] 301 301 💬
|
| 932 | [Adalimumab biosimilare] | [1] Adalimumab Adalimumab | [1] Adalimumab
Adalimumab
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 107 107 💬
|
| 933 | [Adalimumab] | [1] Adalimumab Adalimumab | [1] Adalimumab
Adalimumab
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 96 96 💬
|
| 934 | [AG10 HCL] | - | - | - | - | [1] 28 28 💬
|
| 935 | [AIN457] | - | - | - | - | [2] 41 41, 107 💬
|
| 936 | [AL001] | - | - | - | - | [1] 127 127 💬
|
| 937 | [allo-APZ2-EB] | [1] Skin-derived ABCB5-positive Mesenchymal Stem cells Skin-derived ABCB5-positive Mesenchymal Stem cells | - | - | - | [1] 36 36 💬
|
| 938 | [ALN-62643] | - | - | - | - | [1] 109 109 💬
|
| 939 | [ALN-CC5] | - | - | - | - | [2] 11 11, 62 💬
|
| 940 | [ALN-GO1] | - | - | - | - | [1] 234 234 💬
|
| 941 | [ALN-TTRSC02] | - | - | - | - | [1] 28 28 💬
|
| 942 | [ALX0081] | - | - | - | - | [1] 64 64 💬
|
| 943 | [ALXN1210] | - | - | - | - | [6] 2 2, 11, 13, 50, 62, 66 💬
|
| 944 | [ALXN2040] | - | - | - | - | [1] 62 62 💬
|
| 945 | [AMG 145] | - | - | - | - | [1] 79 79 💬
|
| 946 | [AMG 162] | - | - | - | - | [1] 274 274 💬
|
| 947 | [AMG 407] | - | - | - | - | [2] 56 56, 107 💬
|
| 948 | [AMG 570] | - | - | - | - | [1] 49 49 💬
|
| 949 | [AMG 592] | - | - | - | - | [2] 49 49, 97 💬
|
| 950 | [AMG 785] | - | - | - | - | [1] 274 274 💬
|
| 951 | [AMG407] | - | - | - | - | [2] 56 56, 107 💬
|
| 952 | [Amifampridina fosfato] | - | - | - | - | [2] 3 3, 11 💬
|
| 953 | [AMT-101] | [1] AMT-101 AMT-101 | - | - | - | [1] 97 97 💬
|
| 954 | [AMX0035] | - | - | - | - | [1] 2 2 💬
|
| 955 | [AMZ002] | [1] AMZ002 AMZ002 | - | - | - | [1] 145 145 💬
|
| 956 | [Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma | - | - | - | - | [2] 96 96, 97 💬
|
| 957 | [ANVS401] | - | - | - | - | [1] 6 6 💬
|
| 958 | [ANX005] | - | - | - | - | [1] 61 61 💬
|
| 959 | [APD334] | - | - | - | - | [2] 96 96, 97 💬
|
| 960 | [APD811] | - | - | - | - | [1] 86 86 💬
|
| 961 | [APL-130277] | - | - | - | - | [1] 6 6 💬
|
| 962 | [APL-2] | - | - | - | - | [2] 2 2, 223 💬
|
| 963 | [ARC1905] | - | - | - | - | [1] 301 301 💬
|
| 964 | [ARGX-113] | - | - | - | - | [3] 11 11, 35, 63 💬
|
| 965 | [ARGX-117 IV] | - | - | - | - | [1] 14 14 💬
|
| 966 | [ARO-AAT] | - | - | - | - | [1] 231 231 💬
|
| 967 | [ARRY-371797] | - | - | - | - | [1] 57 57 💬
|
| 968 | [AT1001] | - | - | - | - | [1] 19 19 💬
|
| 969 | [AT2221] | [1] Miglustat Miglustat | [1] Miglustat
Miglustat
💬
| [1] UGCG UGCG 💬
| [2] Cornified envelope formation Cornified envelope formation, Sphingolipid metabolism 💬 | [1] 256 256 💬
|
| 970 | [ATB200] | - | - | - | - | [1] 256 256 💬
|
| 971 | [ATH434] | [1] ATH434 ATH434 | - | - | - | [1] 17 17 💬
|
| 972 | [Atomoxetina] | - | - | - | - | [1] 230 230 💬
|
| 973 | [atovaquone] | [1] Atovaquone Atovaquone | [1] Atovaquone
Atovaquone
💬
| - | - | [1] 61 61 💬
|
| 974 | [Atrasentan] | [1] Atrasentan Atrasentan | [1] Atrasentan hydrochloride
Atrasentan hydrochloride
💬
| [1] EDNRA EDNRA 💬
| [7] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [2] 66 66, 222 💬
|
| 975 | [ATYR1923] | - | - | - | - | [1] 84 84 💬
|
| 976 | [AVB-101] | [1] AVB-101 AVB-101 | - | - | - | [1] 127 127 💬
|
| 977 | [AVI-4658] | - | - | - | - | [1] 113 113 💬
|
| 978 | [AVXS-101] | - | - | - | - | [1] 3 3 💬
|
| 979 | [AZD6244] | - | - | - | - | [1] 34 34 💬
|
| 980 | [AZP-531] | - | - | - | - | [1] 193 193 💬
|
| 981 | [BAF312] | - | - | - | - | [1] 13 13 💬
|
| 982 | [BCX7353] | [1] Berotralstat Berotralstat | [2] Berotralstat
Berotralstat
,
Berotralstat hydrochloride
💬
| [1] KLKB1 KLKB1 💬
| [1] Complement and coagulation cascades Complement and coagulation cascades 💬 | [1] 65 65 💬
|
| 983 | [BCX9930] | - | - | - | - | [4] 62 62, 66, 222, 223 💬
|
| 984 | [Bexsero] | - | - | - | - | [2] 62 62, 223 💬
|
| 985 | [BG00011] | - | - | - | - | [1] 85 85 💬
|
| 986 | [BHV-2000] | - | - | - | - | [1] 3 3 💬
|
| 987 | [BI 1015550] | - | - | - | - | [1] 85 85 💬
|
| 988 | [BI 655130] | - | - | - | - | [3] 37 37, 96, 97 💬
|
| 989 | [BI 706321] | - | - | - | - | [1] 96 96 💬
|
| 990 | [BIA 5-1058] | [1] BIA BIA | - | - | - | [1] 86 86 💬
|
| 991 | [BIA 9-1067] | [1] BIA BIA | - | - | - | [1] 6 6 💬
|
| 992 | [BIA-5-1058] | [1] BIA BIA | - | - | - | [1] 86 86 💬
|
| 993 | [BIBF 1120] | - | - | - | - | [1] 51 51 💬
|
| 994 | [BIIB 017] | - | - | - | - | [1] 13 13 💬
|
| 995 | [BIIB017] | - | - | - | - | [1] 13 13 💬
|
| 996 | [BIIB033] | - | - | - | - | [1] 13 13 💬
|
| 997 | [BIIB054] | - | - | - | - | [1] 6 6 💬
|
| 998 | [BIIB059] | - | - | - | - | [1] 49 49 💬
|
| 999 | [BIIB067 (ISIS666853)] | - | - | - | - | [1] 2 2 💬
|
| 1000 | [BIIB092] | - | - | - | - | [1] 5 5 💬
|
| 1001 | [Birtamimab] | [1] Birtamimab Birtamimab | [1] Birtamimab
Birtamimab
💬
| - | - | [1] 28 28 💬
|
| 1002 | [BIVV020] | - | - | - | - | [1] 14 14 💬
|
| 1003 | [BMS-188667] | - | - | - | - | [1] 46 46 💬
|
| 1004 | [BMS-986165] | - | - | - | - | [2] 96 96, 97 💬
|
| 1005 | [BMS-986278] | [1] BMS-986278 BMS-986278 | [1] Admilparant
Admilparant
💬
| [1] LPAR1 LPAR1 💬
| [8] Gap junction Gap junction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Regulation of actin cytoskeleton 💬 | [1] 85 85 💬
|
| 1006 | [Bortezomib Accord] | [1] Bortezomib Bortezomib | [1] Bortezomib
Bortezomib
💬
| [1] PSMB5 PSMB5 💬
| [8] Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | [1] 28 28 💬
|
| 1007 | [BRX-345] | - | - | - | - | [1] 2 2 💬
|
| 1008 | [BUL 0.5 mg] | - | - | - | - | [1] 98 98 💬
|
| 1009 | [BUL 1 mg] | - | - | - | - | [1] 98 98 💬
|
| 1010 | [C-11]Methylreboxetine | - | - | - | - | [1] 13 13 💬
|
| 1011 | [C-11]PBR28 | - | - | - | - | [1] 13 13 💬
|
| 1012 | [C01EB18] | - | - | - | - | [1] 58 58 💬
|
| 1013 | [C11]PK-1195 PET scan | - | - | - | - | [1] 13 13 💬
|
| 1014 | [CAEL-101] | - | - | - | - | [1] 28 28 💬
|
| 1015 | [CAM2029 ] | - | - | - | - | [1] 77 77 💬
|
| 1016 | [CAM2029] | - | - | - | - | [1] 77 77 💬
|
| 1017 | [Canakinumab] | [1] Canakinumab Canakinumab | [1] Canakinumab
Canakinumab
💬
| [1] IL1B IL1B 💬
| [43] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | [1] 269 269 💬
|
| 1018 | [CC-10004] | - | - | - | - | [1] 97 97 💬
|
| 1019 | [CC-93538] | - | - | - | - | [1] 98 98 💬
|
| 1020 | [CCD 1042, MD 9150000, Mepalon 1042, SPT316] | - | - | - | - | [1] 152 152 💬
|
| 1021 | [CCP-690-550-10] | - | - | - | - | [1] 107 107 💬
|
| 1022 | [CCX140-B] | - | - | - | - | [1] 222 222 💬
|
| 1023 | [CDP7657] | - | - | - | - | [1] 49 49 💬
|
| 1024 | [CDX-0159] | - | - | - | - | [1] 98 98 💬
|
| 1025 | [CDZ173] | - | - | - | - | [1] 65 65 💬
|
| 1026 | [Cetirizina] | - | - | - | - | [1] 300 300 💬
|
| 1027 | [CFZ533] | - | - | - | - | [1] 53 53 💬
|
| 1028 | [citicolin] | - | - | - | - | [1] 6 6 💬
|
| 1029 | [CJNJ-68150420-ZZZ-G001 (ACT- 064992D)] | - | - | - | - | [1] 86 86 💬
|
| 1030 | [CK-2127107] | [1] Reldesemtiv Reldesemtiv | [1] Reldesemtiv
Reldesemtiv
💬
| [3] TNNC2 TNNC2, TNNI2, TNNT3 💬
| [3] Calcium signaling pathway Calcium signaling pathway, Cytoskeleton in muscle cells, Motor proteins 💬 | [1] 2 2 💬
|
| 1031 | [CK-3773274] | - | - | - | - | [1] 58 58 💬
|
| 1032 | [clobetasolo propionato] | - | - | - | - | [1] 162 162 💬
|
| 1033 | [Clorfenamina maleato] | - | - | - | - | [1] 14 14 💬
|
| 1034 | [CLS12311] | - | - | - | - | [1] 13 13 💬
|
| 1035 | [CNTO1275] | - | - | - | - | [2] 96 96, 97 💬
|
| 1036 | [CNTO148] | - | - | - | - | [2] 96 96, 97 💬
|
| 1037 | [CNTO1959] | - | - | - | - | [4] 37 37, 41, 96, 97 💬
|
| 1038 | [CNTO312] | - | - | - | - | [1] 97 97 💬
|
| 1039 | [COR-003] | - | - | - | - | [1] 75 75 💬
|
| 1040 | [CORMETO] | - | - | - | - | [1] 75 75 💬
|
| 1041 | [CORT125134] | [1] Relacorilant Relacorilant | [1] Relacorilant
Relacorilant
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 75 75 💬
|
| 1042 | [CP-690, 550-10] | - | - | - | - | [2] 97 97, 107 💬
|
| 1043 | [CRN00808] | - | - | - | - | [1] 77 77 💬
|
| 1044 | [CSL312 garadacimab] | [1] Garadacimab Garadacimab | [1] Garadacimab
Garadacimab
💬
| [1] F12 F12 💬
| [1] Complement and coagulation cascades Complement and coagulation cascades 💬 | [2] 65 65, 85 💬
|
| 1045 | [CSL312] | - | - | - | - | [1] 65 65 💬
|
| 1046 | [CT-P13] | - | - | - | - | [2] 96 96, 97 💬
|
| 1047 | [CVL-751] | - | - | - | - | [1] 6 6 💬
|
| 1048 | [Cx601] | - | - | - | - | [1] 96 96 💬
|
| 1049 | [d-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)] | - | - | - | - | [1] 28 28 💬
|
| 1050 | [d-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)] | - | - | - | - | [1] 28 28 💬
|
| 1051 | [Dapagliflozin] | [1] Dapagliflozin Dapagliflozin | [1] Dapagliflozin
Dapagliflozin
💬
| - | - | [1] 66 66 💬
|
| 1052 | [Daratumumab] | [1] Daratumumab Daratumumab | [1] Daratumumab
Daratumumab
💬
| [1] CD38 CD38 💬
| [6] Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | [1] 28 28 💬
|
| 1053 | [DaTSCAN] | - | - | - | - | [1] 6 6 💬
|
| 1054 | [DCR-PHXC] | - | - | - | - | [1] 234 234 💬
|
| 1055 | [Deflazacort] | [1] Deflazacort Deflazacort | [1] Deflazacort
Deflazacort
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 113 113 💬
|
| 1056 | [Dexamethasone sodium phosphate] | [1] Dexamethasone Dexamethasone | [3] Dexamethasone
Dexamethasone
,
Dexamethasone sodium phosphate
,
Dexamethasone phosphate
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 65 65 💬
|
| 1057 | [DFV890] | [1] DFV890 DFV890 | - | - | - | [1] 106 106 💬
|
| 1058 | [difenidramina cloridrato] | - | - | - | - | [1] 19 19 💬
|
| 1059 | [DNL151, DN0001575, DN1575] | - | - | - | - | [1] 6 6 💬
|
| 1060 | [DNL151] | - | - | - | - | [1] 6 6 💬
|
| 1061 | [DNL310] | - | - | - | - | [1] 19 19 💬
|
| 1062 | [DNL593] | - | - | - | - | [1] 127 127 💬
|
| 1063 | [Dual AAV8.MYO7A] | - | - | - | - | [2] 90 90, 303 💬
|
| 1064 | [DX-2930] | - | - | - | - | [1] 65 65 💬
|
| 1065 | [Eculizumab] | [1] Eculizumab Eculizumab | [1] Eculizumab
Eculizumab
💬
| [1] C5 C5 💬
| [11] Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1] 62 62 💬
|
| 1066 | [ELX/TEZ/IVA] | - | - | - | - | [1] 299 299 💬
|
| 1067 | [EMD 128130] | - | - | - | - | [1] 156 156 💬
|
| 1068 | [Enbrel] | - | - | - | - | [1] 46 46 💬
|
| 1069 | [Etanercept biosimilare] | [1] Etanercept Etanercept | [1] Etanercept
Etanercept
💬
| [2] LTA LTA, TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 107 107 💬
|
| 1070 | [ETB115] | - | - | - | - | [2] 60 60, 63 💬
|
| 1071 | [EU/3/13/1208 orphan] | - | - | - | - | [1] 301 301 💬
|
| 1072 | [F-18] Fluorodopa Positron Emission Tomography | - | - | - | - | [1] 6 6 💬
|
| 1073 | [F-18]DPA714 administration IV | - | - | - | - | [1] 6 6 💬
|
| 1074 | [F-18]FDG | - | - | - | - | [1] 13 13 💬
|
| 1075 | [F-18]PBR06 | - | - | - | - | [1] 13 13 💬
|
| 1076 | [F-18]SDM-8 | - | - | - | - | [1] 13 13 💬
|
| 1077 | [F18]-FDDNP | - | - | - | - | [1] 5 5 💬
|
| 1078 | [FAB122] | - | - | - | - | [1] 2 2 💬
|
| 1079 | [FCN-159] | - | - | - | - | [1] 34 34 💬
|
| 1080 | [FG-3019] | - | - | - | - | [2] 85 85, 113 💬
|
| 1081 | [Firazyr] | - | - | - | - | [1] 65 65 💬
|
| 1082 | [FLT190] | [1] FLT190 FLT190 | - | - | - | [1] 19 19 💬
|
| 1083 | [Formistin 10 mg] | - | - | - | - | [1] 13 13 💬
|
| 1084 | [FP-CYA-050] | - | - | - | - | [1] 97 97 💬
|
| 1085 | [FP-CYA-053] | - | - | - | - | [1] 97 97 💬
|
| 1086 | [FTX-1821] | - | - | - | - | [1] 113 113 💬
|
| 1087 | [FTY720] | - | - | - | - | [1] 13 13 💬
|
| 1088 | [G02CB03] | - | - | - | - | [1] 75 75 💬
|
| 1089 | [G048E03] | - | - | - | - | [1] 85 85 💬
|
| 1090 | [G04BE08] | - | - | - | - | [1] 86 86 💬
|
| 1091 | [G1117337] | - | - | - | - | [1] 67 67 💬
|
| 1092 | [G451990] | - | - | - | - | [2] 51 51, 85 💬
|
| 1093 | [GFT505] | - | - | - | - | [1] 93 93 💬
|
| 1094 | [GKT137831] | - | - | - | - | [1] 93 93 💬
|
| 1095 | [Glentek 50 mg compresse rivestite con film] | - | - | - | - | [1] 18 18 💬
|
| 1096 | [GLPG0634] | - | - | - | - | [1] 97 97 💬
|
| 1097 | [Glucocorticoids (GC)] | - | - | - | - | [2] 43 43, 44 💬
|
| 1098 | [GNX] | - | - | - | - | [1] 158 158 💬
|
| 1099 | [GS-4875] | - | - | - | - | [1] 97 97 💬
|
| 1100 | [GS-6034] | - | - | - | - | [2] 96 96, 97 💬
|
| 1101 | [GS-6155 white 6 mg tablets] | - | - | - | - | [1] 58 58 💬
|
| 1102 | [GS-6615 pink 6 mg tablets] | - | - | - | - | [1] 58 58 💬
|
| 1103 | [GS-6615 white 10 mg tablets] | - | - | - | - | [1] 58 58 💬
|
| 1104 | [GS-6615 white 3 mg tablets] | - | - | - | - | [1] 58 58 💬
|
| 1105 | [GS-9674] | - | - | - | - | [1] 94 94 💬
|
| 1106 | [GS010] | - | - | - | - | [1] 302 302 💬
|
| 1107 | [GSK2330672] | - | - | - | - | [1] 93 93 💬
|
| 1108 | [GSK2857916] | - | - | - | - | [1] 28 28 💬
|
| 1109 | [GSK3196165] | - | - | - | - | [1] 46 46 💬
|
| 1110 | [GSK3511294] | - | - | - | - | [2] 44 44, 45 💬
|
| 1111 | [GWP42003-P] | - | - | - | - | [1] 156 156 💬
|
| 1112 | [GZ402666] | - | - | - | - | [1] 256 256 💬
|
| 1113 | [GZ402671] | - | - | - | - | [1] 19 19 💬
|
| 1114 | [H01BB02] | - | - | - | - | [1] 193 193 💬
|
| 1115 | [H02AB02] | - | - | - | - | [1] 28 28 💬
|
| 1116 | [HGT-1410] | - | - | - | - | [1] 19 19 💬
|
| 1117 | [HMR1726] | - | - | - | - | [1] 13 13 💬
|
| 1118 | [hNSC] | - | - | - | - | [1] 2 2 💬
|
| 1119 | [Hologene 5 DS] | - | - | - | - | [1] 36 36 💬
|
| 1120 | [Humira] | - | - | - | - | [2] 46 46, 107 💬
|
| 1121 | [Hydroxychloroquine] | [1] Hydroxychloroquine Hydroxychloroquine | [2] Hydroxychloroquine sulfate
Hydroxychloroquine sulfate
,
Hydroxychloroquine
💬
| - | - | [1] 53 53 💬
|
| 1122 | [HZN-825] | - | - | - | - | [1] 51 51 💬
|
| 1123 | [I-123] ADAM | - | - | - | - | [1] 2 2 💬
|
| 1124 | [Idebenone] | [1] Idebenone Idebenone | [1] Idebenone
Idebenone
💬
| - | - | [1] 113 113 💬
|
| 1125 | [IFB-088] | - | - | - | - | [1] 2 2 💬
|
| 1126 | [IFN beta-1a] | - | - | - | - | [1] 13 13 💬
|
| 1127 | [IFN ß-1a] | - | - | - | - | [1] 13 13 💬
|
| 1128 | [IFX-1] | - | - | - | - | [2] 43 43, 44 💬
|
| 1129 | [IgPro10] | - | - | - | - | [1] 51 51 💬
|
| 1130 | [IgPro20] | - | - | - | - | [2] 50 50, 51 💬
|
| 1131 | [IMP-2] | - | - | - | - | [1] 63 63 💬
|
| 1132 | [IMVT-1401] | - | - | - | - | [1] 11 11 💬
|
| 1133 | [INCB050465 1 mg] | - | - | - | - | [1] 61 61 💬
|
| 1134 | [INCB050465 2.5 mg] | - | - | - | - | [1] 61 61 💬
|
| 1135 | [INCB050465] | [1] Parsaclisib Parsaclisib | [1] Parsaclisib
Parsaclisib
💬
| [1] PIK3CD PIK3CD 💬
| [106] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease, Diabetic cardiomyopathy, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagosome formation, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, IgSF CAM signaling, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, Integrin signaling, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phagocytosis, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | [1] 61 61 💬
|
| 1136 | [Inebilizumab] | [1] Inebilizumab Inebilizumab | [1] Inebilizumab
Inebilizumab
💬
| [1] CD19 CD19 💬
| [5] B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | [1] 300 300 💬
|
| 1137 | [INM-755] | - | - | - | - | [1] 36 36 💬
|
| 1138 | [INS1007] | - | - | - | - | [1] 299 299 💬
|
| 1139 | [INS1009] | - | - | - | - | [1] 86 86 💬
|
| 1140 | [INT-747, OCA] | - | - | - | - | [1] 93 93 💬
|
| 1141 | [Ioexolo] | - | - | - | - | [1] 222 222 💬
|
| 1142 | [ION-682884] | - | - | - | - | [1] 28 28 💬
|
| 1143 | [ION363] | - | - | - | - | [1] 2 2 💬
|
| 1144 | [ION373] | - | - | - | - | [1] 131 131 💬
|
| 1145 | [ION582] | [1] ION582 ION582 | - | - | - | [1] 201 201 💬
|
| 1146 | [IPN60120] | - | - | - | - | [1] 272 272 💬
|
| 1147 | [IPX203] | - | - | - | - | [1] 6 6 💬
|
| 1148 | [IR CD-LD] | - | - | - | - | [1] 6 6 💬
|
| 1149 | [IRL790] | - | - | - | - | [1] 6 6 💬
|
| 1150 | [ISIS 396443 BIIB058] | - | - | - | - | [1] 3 3 💬
|
| 1151 | [ISIS 396443, BIIB058] | - | - | - | - | [1] 3 3 💬
|
| 1152 | [ISIS 721744] | - | - | - | - | [1] 65 65 💬
|
| 1153 | [ISIS 766720] | - | - | - | - | [1] 77 77 💬
|
| 1154 | [J05AG04] | - | - | - | - | [1] 18 18 💬
|
| 1155 | [J07AH07] | - | - | - | - | [1] 14 14 💬
|
| 1156 | [JBT-101] | [1] Lenabasum Lenabasum | [1] Lenabasum
Lenabasum
💬
| [1] CNR2 CNR2 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [3] 50 50, 51, 299 💬
|
| 1157 | [JM-010] | - | - | - | - | [1] 6 6 💬
|
| 1158 | [JnJ 54767414] | - | - | - | - | [1] 28 28 💬
|
| 1159 | [JNJ-54767414] | - | - | - | - | [1] 28 28 💬
|
| 1160 | [JNJ-64304500] | - | - | - | - | [1] 96 96 💬
|
| 1161 | [JNJ-67864238] | - | - | - | - | [1] 96 96 💬
|
| 1162 | [JNJ-67896049 (ACT-293987)] | - | - | - | - | [1] 86 86 💬
|
| 1163 | [JNJ-67896062 / ACT-064992] | - | - | - | - | [2] 86 86, 88 💬
|
| 1164 | [JNJ-67896062/ ACT-064992] | - | - | - | - | [2] 86 86, 88 💬
|
| 1165 | [JNJ-67896153/ACT-128800] | - | - | - | - | [1] 13 13 💬
|
| 1166 | [JNJ-80202135] | - | - | - | - | [1] 11 11 💬
|
| 1167 | [JNJ31-31001074] | - | - | - | - | [1] 6 6 💬
|
| 1168 | [JR-141] | - | - | - | - | [1] 19 19 💬
|
| 1169 | [KIg10] | - | - | - | - | [1] 65 65 💬
|
| 1170 | [KINERET] | - | - | - | - | [1] 57 57 💬
|
| 1171 | [KJX839] | - | - | - | - | [1] 79 79 💬
|
| 1172 | [KVD900 100 mg Film Coated Tablet] | - | - | - | - | [1] 65 65 💬
|
| 1173 | [KVD900 300 mg Film Coated Tablet] | - | - | - | - | [1] 65 65 💬
|
| 1174 | [KVD900] | - | - | - | - | [1] 65 65 💬
|
| 1175 | [L01AA01] | - | - | - | - | [1] 51 51 💬
|
| 1176 | [L01XC15] | - | - | - | - | [1] 222 222 💬
|
| 1177 | [L01XX14] | - | - | - | - | [1] 75 75 💬
|
| 1178 | [L03AA02] | - | - | - | - | [1] 51 51 💬
|
| 1179 | [L04AA04] | - | - | - | - | [1] 51 51 💬
|
| 1180 | [L04AA06] | - | - | - | - | [1] 51 51 💬
|
| 1181 | [L04AA31] | - | - | - | - | [1] 13 13 💬
|
| 1182 | [L04AB04] | - | - | - | - | [2] 107 107, 271 💬
|
| 1183 | [L04AC06] | - | - | - | - | [2] 44 44, 45 💬
|
| 1184 | [LCI699] | - | - | - | - | [1] 75 75 💬
|
| 1185 | [Leflunomide] | [1] Leflunomide Leflunomide | [1] Leflunomide
Leflunomide
💬
| [1] DHODH DHODH 💬
| [1] Pyrimidine metabolism Pyrimidine metabolism 💬 | [1] 53 53 💬
|
| 1186 | [LEVOVANOX] | - | - | - | - | [2] 94 94, 97 💬
|
| 1187 | [LMI070] | - | - | - | - | [1] 8 8 💬
|
| 1188 | [LNP023 hydrochloride] | - | - | - | - | [1] 223 223 💬
|
| 1189 | [LNP023] | - | - | - | - | [2] 62 62, 66 💬
|
| 1190 | [Lomitapide 2mg hard capsules] | [1] Lomitapide Lomitapide | [2] Lomitapide
Lomitapide
,
Lomitapide mesylate
💬
| [1] MTTP MTTP 💬
| [1] Fat digestion and absorption Fat digestion and absorption 💬 | [1] 79 79 💬
|
| 1191 | [LOU064C1] | - | - | - | - | [1] 13 13 💬
|
| 1192 | [LY3009104] | - | - | - | - | [4] 46 46, 49, 93, 107 💬
|
| 1193 | [LY3074828] | - | - | - | - | [2] 96 96, 97 💬
|
| 1194 | [M281] | - | - | - | - | [3] 11 11, 53, 61 💬
|
| 1195 | [M2951] | - | - | - | - | [1] 13 13 💬
|
| 1196 | [Magnesium Oxide] | [2] Magnesium Magnesium, Magnesium oxide | [1] Magnesium oxide
Magnesium oxide
💬
| - | - | [1] 113 113 💬
|
| 1197 | [Maralixibat] | [1] Maralixibat Maralixibat | [2] Maralixibat
Maralixibat
,
Maralixibat chloride
💬
| [2] SLC10A1 SLC10A1, SLC10A2 💬
| [3] Bile secretion Bile secretion, Hepatitis B, Virion - Hepatitis viruses 💬 | [2] 296 296, 338 💬
|
| 1198 | [MBX-8025] | - | - | - | - | [1] 93 93 💬
|
| 1199 | [MD1003] | - | - | - | - | [1] 13 13 💬
|
| 1200 | [MEDI-563] | - | - | - | - | [5] 44 44, 45, 98, 162, 299 💬
|
| 1201 | [MEDI2070] | - | - | - | - | [2] 96 96, 97 💬
|
| 1202 | [MEDI9929 anti-TSLP mAb (AMG157)] | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 1203 | [Melflufen] | - | - | - | - | [1] 28 28 💬
|
| 1204 | [Menveo] | - | - | - | - | [2] 62 62, 223 💬
|
| 1205 | [Mepolizumab] | [1] Mepolizumab Mepolizumab | [1] Mepolizumab
Mepolizumab
💬
| [1] IL5 IL5 💬
| [13] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | [2] 44 44, 45 💬
|
| 1206 | [METFORMINA] | [1] Metformin Metformin | [2] Metformin hydrochloride
Metformin hydrochloride
,
Metformin
💬
| [2] PRKAA1 PRKAA1, PRKAA2 💬
| [20] AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | [1] 67 67 💬
|
| 1207 | [Metilprednisolone sodio succinato] | - | - | - | - | [2] 14 14, 66 💬
|
| 1208 | [Metilprednisolone] | - | - | - | - | [2] 13 13, 300 💬
|
| 1209 | [MK-4836] | - | - | - | - | [1] 86 86 💬
|
| 1210 | [MK-5475] | - | - | - | - | [1] 86 86 💬
|
| 1211 | [MLN0002] | - | - | - | - | [1] 96 96 💬
|
| 1212 | [MNK-1411] | - | - | - | - | [1] 113 113 💬
|
| 1213 | [MOR202] | - | - | - | - | [1] 222 222 💬
|
| 1214 | [MOUNJARO] | - | - | - | - | [1] 233 233 💬
|
| 1215 | [MT-1186] | - | - | - | - | [1] 2 2 💬
|
| 1216 | [MT-1303] | - | - | - | - | [1] 97 97 💬
|
| 1217 | [MT-7117] | - | - | - | - | [2] 51 51, 254 💬
|
| 1218 | [MTP-131] | - | - | - | - | [1] 21 21 💬
|
| 1219 | [MXB-8025] | - | - | - | - | [1] 93 93 💬
|
| 1220 | [mycophenolate mofetil] | [1] Mycophenolate mofetil Mycophenolate mofetil | [2] Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolate mofetil hydrochloride
💬
| [2] IMPDH1 IMPDH1, IMPDH2 💬
| [2] Drug metabolism - other enzymes Drug metabolism - other enzymes, Purine metabolism 💬 | [1] 53 53 💬
|
| 1221 | [MYK-461] | [1] Mavacamten Mavacamten | [1] Mavacamten
Mavacamten
💬
| [1] MYH7 MYH7 💬
| [9] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Cardiac muscle contraction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Motor proteins, Thyroid hormone signaling pathway, Viral myocarditis, cGMP-PKG signaling pathway 💬 | [1] 58 58 💬
|
| 1222 | [Myozyme] | - | - | - | - | [1] 256 256 💬
|
| 1223 | [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | [1] Acetate Acetate | - | - | - | [1] 265 265 💬
|
| 1224 | [N.A.] | - | - | - | - | [1] 97 97 💬
|
| 1225 | [n.d.] | - | - | - | - | [1] 97 97 💬
|
| 1226 | [N/A] | - | - | - | - | [11] 2 2, 11, 13, 20, 28, 46, 51, 61, 65, 97, 299 💬
|
| 1227 | [N04BA] | - | - | - | - | [1] 6 6 💬
|
| 1228 | [N06AX26] | - | - | - | - | [1] 6 6 💬
|
| 1229 | [NA] | - | - | - | - | [34] 3 3, 6, 11, 13, 14, 19, 28, 35, 41, 46, 49, 50, 53, 57, 62, 63, 65, 75, 79, 85, 90, 96, 97, 98, 113, 127, 162, 195, 223, 229, 251, 294, 299, 302 💬
|
| 1230 | [National Drug Code: 59762-0074] | - | - | - | - | [1] 81 81 💬
|
| 1231 | [NBI-74788] | - | - | - | - | [1] 81 81 💬
|
| 1232 | [ND0612] | - | - | - | - | [1] 6 6 💬
|
| 1233 | [nd] | - | - | - | - | [1] 251 251 💬
|
| 1234 | [Nefecon] | - | - | - | - | [1] 66 66 💬
|
| 1235 | [Newnorm] | - | - | - | - | [1] 65 65 💬
|
| 1236 | [NI-0501] | - | - | - | - | [1] 107 107 💬
|
| 1237 | [Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH | - | - | - | - | [1] 254 254 💬
|
| 1238 | [NMD670] | - | - | - | - | [1] 3 3 💬
|
| 1239 | [NN8640] | - | - | - | - | [1] 195 195 💬
|
| 1240 | [NOE-101] | - | - | - | - | [1] 158 158 💬
|
| 1241 | [non applicabile] | - | - | - | - | [1] 13 13 💬
|
| 1242 | [non fornito] | - | - | - | - | [1] 14 14 💬
|
| 1243 | [NorUDCA] | - | - | - | - | [1] 94 94 💬
|
| 1244 | [Not Applicable] | - | - | - | - | [4] 13 13, 20, 50, 272 💬
|
| 1245 | [not assigned] | - | - | - | - | [1] 272 272 💬
|
| 1246 | [NS-065/NCNP-01] | - | - | - | - | [1] 113 113 💬
|
| 1247 | [OAV101] | - | - | - | - | [1] 3 3 💬
|
| 1248 | [OCA] | - | - | - | - | [1] 296 296 💬
|
| 1249 | [OCTREOTIDE ACETATO] | [1] Octreotide Octreotide | [5] Octreotide
Octreotide
,
Octreotide acetate
,
Octreotide pamoate
,
Octreotide acetate
,
Octreotide hydrochloride
💬
| [1] SSTR2 SSTR2 💬
| [5] Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Hormone signaling, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | [1] 227 227 💬
|
| 1250 | [ODM-109] | - | - | - | - | [1] 2 2 💬
|
| 1251 | [OMB 157] | - | - | - | - | [1] 13 13 💬
|
| 1252 | [OMB157] | - | - | - | - | [1] 13 13 💬
|
| 1253 | [OMS721] | - | - | - | - | [1] 66 66 💬
|
| 1254 | [OMT-28] | - | - | - | - | [1] 21 21 💬
|
| 1255 | [OPS-2071] | - | - | - | - | [1] 96 96 💬
|
| 1256 | [OTL-200] | - | - | - | - | [1] 19 19 💬
|
| 1257 | [over-encapsulated Irbesartan] | [1] Irbesartan Irbesartan | [1] Irbesartan
Irbesartan
💬
| [1] AGTR1 AGTR1 💬
| [17] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | [1] 222 222 💬
|
| 1258 | [ozanimod cloridrato] | [1] Ozanimod Ozanimod | [2] Ozanimod hydrochloride
Ozanimod hydrochloride
,
Ozanimod
💬
| [5] S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 1259 | [Ozanimod] | [1] Ozanimod Ozanimod | [2] Ozanimod hydrochloride
Ozanimod hydrochloride
,
Ozanimod
💬
| [5] S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 1260 | [Paracetamolo] | - | - | - | - | [4] 14 14, 19, 300, 309 💬
|
| 1261 | [pentamidine] | [1] Pentamidine Pentamidine | [2] Pentamidine isethionate
Pentamidine isethionate
,
Pentamidine
💬
| - | - | [1] 61 61 💬
|
| 1262 | [PF-06291826-00] | - | - | - | - | [1] 28 28 💬
|
| 1263 | [PF-06291826-83] | - | - | - | - | [1] 28 28 💬
|
| 1264 | [PF-06480605] | - | - | - | - | [1] 97 97 💬
|
| 1265 | [PF-06651600 10 mg] | - | - | - | - | [1] 97 97 💬
|
| 1266 | [PF-06651600 50 mg] | - | - | - | - | [2] 96 96, 97 💬
|
| 1267 | [PF-06687234] | - | - | - | - | [1] 97 97 💬
|
| 1268 | [PF-06700841 25 mg] | - | - | - | - | [2] 96 96, 97 💬
|
| 1269 | [PF-06700841 25mg] | - | - | - | - | [1] 49 49 💬
|
| 1270 | [PF-06700841 5 mg] | - | - | - | - | [3] 49 49, 96, 97 💬
|
| 1271 | [PF-06730512] | - | - | - | - | [1] 222 222 💬
|
| 1272 | [PF-06823859] | - | - | - | - | [1] 50 50 💬
|
| 1273 | [PF-06939926] | - | - | - | - | [1] 113 113 💬
|
| 1274 | [PF-07256472] | - | - | - | - | [1] 276 276 💬
|
| 1275 | [PHA-022121] | - | - | - | - | [1] 65 65 💬
|
| 1276 | [PL101] | - | - | - | - | [1] 8 8 💬
|
| 1277 | [PLN-74809] | - | - | - | - | [1] 85 85 💬
|
| 1278 | [PN-943] | - | - | - | - | [1] 97 97 💬
|
| 1279 | [Pomalidomide] | [1] Pomalidomide Pomalidomide | [1] Pomalidomide
Pomalidomide
💬
| [2] IL6 IL6, TNF 💬
| [78] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 28 28 💬
|
| 1280 | [PRA023] | - | - | - | - | [2] 51 51, 97 💬
|
| 1281 | [PRD7255830] | - | - | - | - | [1] 79 79 💬
|
| 1282 | [PRD7255977] | - | - | - | - | [1] 79 79 💬
|
| 1283 | [PRD7256003] | - | - | - | - | [1] 79 79 💬
|
| 1284 | [PREDNISOLONE] | [1] Prednisolone Prednisolone | [1] Prednisolone
Prednisolone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 81 81 💬
|
| 1285 | [Prednisone] | [1] Prednisone Prednisone | [1] Prednisone
Prednisone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [5] 19 19, 66, 90, 300, 303 💬
|
| 1286 | [PRN1008] | - | - | - | - | [2] 35 35, 63 💬
|
| 1287 | [Profilassi per Herpes Zoster] | - | - | - | - | [1] 107 107 💬
|
| 1288 | [PRX-102] | - | - | - | - | [1] 19 19 💬
|
| 1289 | [PTC743] | - | - | - | - | [2] 18 18, 21 💬
|
| 1290 | [PXT3003] | - | - | - | - | [1] 10 10 💬
|
| 1291 | [R-(R*, R*)]-2-(4-fluorophenyl)-beta, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]- | - | - | - | - | [1] 79 79 💬
|
| 1292 | [R-(R*, R*)]-2-(4-fluorophenyl)-ß, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]- | - | - | - | - | [1] 79 79 💬
|
| 1293 | [R-021] | - | - | - | - | [1] 222 222 💬
|
| 1294 | [R727] | - | - | - | - | [1] 79 79 💬
|
| 1295 | [R935788] | - | - | - | - | [1] 61 61 💬
|
| 1296 | [ravulizumab] | [1] Ravulizumab Ravulizumab | [1] Ravulizumab
Ravulizumab
💬
| [1] C5 C5 💬
| [11] Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1] 62 62 💬
|
| 1297 | [RE-021] | - | - | - | - | [3] 66 66, 218, 222 💬
|
| 1298 | [RE-024] | - | - | - | - | [1] 121 121 💬
|
| 1299 | [Recombinant Human Nerve Growth Factor (rhNGF)] | [1] Nerve Growth Factor Nerve Growth Factor | - | - | - | [1] 53 53 💬
|
| 1300 | [REGN1500] | - | - | - | - | [1] 79 79 💬
|
| 1301 | [REGN3918] | - | - | - | - | [2] 11 11, 62 💬
|
| 1302 | [REGN7272] | - | - | - | - | [1] 79 79 💬
|
| 1303 | [Remsima (CT-P13)] | - | - | - | - | [1] 97 97 💬
|
| 1304 | [RGH-706] | - | - | - | - | [1] 193 193 💬
|
| 1305 | [rhLAMAN] | [1] Velmanase alfa Velmanase alfa | [1] Velmanase alfa
Velmanase alfa
💬
| [1] MAN2B1 MAN2B1 💬
| [2] Lysosome biogenesis Lysosome biogenesis, Other glycan degradation 💬 | [1] 19 19 💬
|
| 1306 | [RhuDex choline salt] | [1] Choline Choline | [1] Choline
Choline
💬
| - | - | [1] 93 93 💬
|
| 1307 | [rituximab] | [1] Rituximab Rituximab | [1] Rituximab
Rituximab
💬
| [1] MS4A1 MS4A1 💬
| [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [2] 11 11, 14 💬
|
| 1308 | [Ro 533-3787/F01- 04] | - | - | - | - | [1] 13 13 💬
|
| 1309 | [Ro 533-3787/F01- 06] | - | - | - | - | [1] 13 13 💬
|
| 1310 | [Ro 723-4292/F02] | - | - | - | - | [1] 8 8 💬
|
| 1311 | [RO0220912] | - | - | - | - | [1] 85 85 💬
|
| 1312 | [RO0485337] | - | - | - | - | [1] 222 222 💬
|
| 1313 | [RO487-7533/F10-04] | - | - | - | - | [1] 51 51 💬
|
| 1314 | [RO4964913/F07-01] | - | - | - | - | [1] 13 13 💬
|
| 1315 | [RO4964913/F07] | - | - | - | - | [1] 13 13 💬
|
| 1316 | [RO4964913] | - | - | - | - | [1] 13 13 💬
|
| 1317 | [RO5072759] | - | - | - | - | [1] 222 222 💬
|
| 1318 | [RO5333787] | - | - | - | - | [2] 11 11, 13 💬
|
| 1319 | [RO7010939] | - | - | - | - | [1] 13 13 💬
|
| 1320 | [RO7034067/F12] | - | - | - | - | [1] 3 3 💬
|
| 1321 | [RO7034067/F13] | - | - | - | - | [1] 3 3 💬
|
| 1322 | [RO7034067] | - | - | - | - | [1] 3 3 💬
|
| 1323 | [RO7046015] | - | - | - | - | [1] 6 6 💬
|
| 1324 | [RO7049665] | - | - | - | - | [1] 95 95 💬
|
| 1325 | [RO7112689/F03-01] | - | - | - | - | [1] 109 109 💬
|
| 1326 | [RO7112689/F03-10] | - | - | - | - | [1] 109 109 💬
|
| 1327 | [RO7112689] | - | - | - | - | [1] 62 62 💬
|
| 1328 | [RO7204239/F01-01] | - | - | - | - | [1] 3 3 💬
|
| 1329 | [RO7246311] | - | - | - | - | [1] 97 97 💬
|
| 1330 | [RO7248824/F02-01] | - | - | - | - | [1] 201 201 💬
|
| 1331 | [RO7490677] | - | - | - | - | [1] 85 85 💬
|
| 1332 | [RO7494222 (SRP-9001)] | - | - | - | - | [1] 113 113 💬
|
| 1333 | [Romiplostim] | [1] Romiplostim Romiplostim | [1] Romiplostim
Romiplostim
💬
| [1] MPL MPL 💬
| [3] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hormone signaling, JAK-STAT signaling pathway 💬 | [1] 63 63 💬
|
| 1334 | [RPC0163] | - | - | - | - | [1] 96 96 💬
|
| 1335 | [RPC1063 equiv to ozanimod HCI] | [1] Ozanimod Ozanimod | [2] Ozanimod hydrochloride
Ozanimod hydrochloride
,
Ozanimod
💬
| [5] S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 96 96 💬
|
| 1336 | [RPC1063 equiv. to ozanimod HCI] | [1] Ozanimod Ozanimod | [2] Ozanimod hydrochloride
Ozanimod hydrochloride
,
Ozanimod
💬
| [5] S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 96 96 💬
|
| 1337 | [RPC1063] | - | - | - | - | [1] 96 96 💬
|
| 1338 | [RTA 402] | - | - | - | - | [1] 67 67 💬
|
| 1339 | [RVT-1201] | - | - | - | - | [1] 86 86 💬
|
| 1340 | [RVT-1601 (in precedenza PA101B)] | - | - | - | - | [1] 85 85 💬
|
| 1341 | [Salbutamol] | - | - | - | - | [1] 299 299 💬
|
| 1342 | [Sandimmun Neoral ] | - | - | - | - | [1] 60 60 💬
|
| 1343 | [Sandimmun Neoral] | - | - | - | - | [1] 60 60 💬
|
| 1344 | [SAR402671, GZ402671 o GZ/SAR402671] | - | - | - | - | [2] 19 19, 67 💬
|
| 1345 | [SAR402671, GZ402671 or GZ / SAR402671] | - | - | - | - | [1] 19 19 💬
|
| 1346 | [SAR441344] | - | - | - | - | [1] 49 49 💬
|
| 1347 | [SAR442168] | - | - | - | - | [2] 11 11, 13 💬
|
| 1348 | [SAR443820] | - | - | - | - | [1] 2 2 💬
|
| 1349 | [SAR444671] | - | - | - | - | [2] 61 61, 300 💬
|
| 1350 | [SAR650984] | - | - | - | - | [1] 61 61 💬
|
| 1351 | [SHP 655 (BAX 930)] | - | - | - | - | [1] 64 64 💬
|
| 1352 | [SHP611] | - | - | - | - | [1] 19 19 💬
|
| 1353 | [SHP647] | - | - | - | - | [2] 96 96, 97 💬
|
| 1354 | [Siponimod 0, 25 mg] | [1] Siponimod Siponimod | [2] Siponimod fumarate
Siponimod fumarate
,
Siponimod
💬
| [2] S1PR1 S1PR1, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 1355 | [Siponimod 2 mg] | [1] Siponimod Siponimod | [2] Siponimod fumarate
Siponimod fumarate
,
Siponimod
💬
| [2] S1PR1 S1PR1, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 1356 | [Siponimod] | [1] Siponimod Siponimod | [2] Siponimod fumarate
Siponimod fumarate
,
Siponimod
💬
| [2] S1PR1 S1PR1, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [1] 13 13 💬
|
| 1357 | [Soliris] | - | - | - | - | [2] 13 13, 62 💬
|
| 1358 | [SOM3355] | - | - | - | - | [1] 8 8 💬
|
| 1359 | [SPR001] | - | - | - | - | [1] 81 81 💬
|
| 1360 | [SPX-101] | - | - | - | - | [1] 299 299 💬
|
| 1361 | [SRK-015] | - | - | - | - | [1] 3 3 💬
|
| 1362 | [SRP-4045] | - | - | - | - | [1] 113 113 💬
|
| 1363 | [SRP-4053] | - | - | - | - | [1] 113 113 💬
|
| 1364 | [SRP-5051] | - | - | - | - | [1] 113 113 💬
|
| 1365 | [SRP-9001] | - | - | - | - | [1] 113 113 💬
|
| 1366 | [ST-920] | - | - | - | - | [1] 19 19 💬
|
| 1367 | [Stelara 130mg / 26mL concentrate for solution for | - | - | - | - | [1] 96 96 💬
|
| 1368 | [Stelara 90mg/1ml solution for injecti | - | - | - | - | [1] 96 96 💬
|
| 1369 | [STELARA] | - | - | - | - | [1] 97 97 💬
|
| 1370 | [SUB08293MIG] | - | - | - | - | [1] 222 222 💬
|
| 1371 | [Synacthen Ampoules 250 microgrammi] | - | - | - | - | [1] 113 113 💬
|
| 1372 | [Ta1] | - | - | - | - | [1] 299 299 💬
|
| 1373 | [Tachipirina CPR 500mg] | - | - | - | - | [1] 13 13 💬
|
| 1374 | [TAK-079, TSF-021, TSF79] | - | - | - | - | [1] 11 11 💬
|
| 1375 | [TAK-079] | - | - | - | - | [1] 63 63 💬
|
| 1376 | [TAK-755 orBAX930 or SHP655] | - | - | - | - | [1] 64 64 💬
|
| 1377 | [TAK-935] | - | - | - | - | [2] 140 140, 144 💬
|
| 1378 | [TALTZ] | - | - | - | - | [2] 107 107, 271 💬
|
| 1379 | [TD-1473] | - | - | - | - | [1] 97 97 💬
|
| 1380 | [TD-5108 hydrochloride] | - | - | - | - | [1] 99 99 💬
|
| 1381 | [TD-9855] | - | - | - | - | [2] 6 6, 17 💬
|
| 1382 | [TD139] | - | - | - | - | [1] 85 85 💬
|
| 1383 | [Teicoplanina 200 mg] | - | - | - | - | [1] 299 299 💬
|
| 1384 | [TEV-48574] | - | - | - | - | [2] 96 96, 97 💬
|
| 1385 | [TMB-001] | - | - | - | - | [1] 160 160 💬
|
| 1386 | [TOFACINITIB] | - | - | - | - | [1] 97 97 💬
|
| 1387 | [Tofacitinib] | [1] Tofacitinib Tofacitinib | [2] Tofacitinib citrate
Tofacitinib citrate
,
Tofacitinib
💬
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬
| [39] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Efferocytosis, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 46 46 💬
|
| 1388 | [TOL | - | - | - | - | [1] 67 67 💬
|
| 1389 | [TOLVAPTAN 15] | [1] Tolvaptan Tolvaptan | [1] Tolvaptan
Tolvaptan
💬
| [1] AVPR2 AVPR2 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | [1] 67 67 💬
|
| 1390 | [TOLVAPTAN 30] | [1] Tolvaptan Tolvaptan | [1] Tolvaptan
Tolvaptan
💬
| [1] AVPR2 AVPR2 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | [1] 67 67 💬
|
| 1391 | [TOLVAPTAN 45/15] | [1] Tolvaptan Tolvaptan | [1] Tolvaptan
Tolvaptan
💬
| [1] AVPR2 AVPR2 💬
| [4] Hormone signaling Hormone signaling, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | [1] 67 67 💬
|
| 1392 | [TPN-101] | - | - | - | - | [1] 325 325 💬
|
| 1393 | [TransCon PTH] | - | - | - | - | [1] 235 235 💬
|
| 1394 | [trimethoprim-sulfamethoxazole] | [2] Sulfamethoxazole Sulfamethoxazole, Trimethoprim | [4] Trimethoprim
Trimethoprim
,
Sulfamethoxazole
,
Trimethoprim sulfate
,
Trimethoprim hydrochloride
💬
| - | - | [1] 61 61 💬
|
| 1395 | [TUDCA] | - | - | - | - | [1] 2 2 💬
|
| 1396 | [UCB0599] | - | - | - | - | [1] 6 6 💬
|
| 1397 | [UCB7665 ] | - | - | - | - | [1] 63 63 💬
|
| 1398 | [UCB7665] | [1] Rozanolixizumab Rozanolixizumab | [1] Rozanolixizumab
Rozanolixizumab
💬
| - | - | [2] 11 11, 63 💬
|
| 1399 | [Ustekinumab] | [1] Ustekinumab Ustekinumab | [1] Ustekinumab
Ustekinumab
💬
| [3] IL12A IL12A, IL12B, IL23A 💬
| [28] African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | [1] 96 96 💬
|
| 1400 | [UTTR1147A/RO7021610 (Active)] | - | - | - | - | [1] 97 97 💬
|
| 1401 | [UX053] | [1] UX053 UX053 | - | - | - | [1] 257 257 💬
|
| 1402 | [VAL-1221] | - | - | - | - | [1] 309 309 💬
|
| 1403 | [vamorolone] | [1] Vamorolone Vamorolone | [1] Vamorolone
Vamorolone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 113 113 💬
|
| 1404 | [VAY736] | - | - | - | - | [4] 49 49, 53, 61, 63 💬
|
| 1405 | [Ventolin] | - | - | - | - | [1] 299 299 💬
|
| 1406 | [Vigabatrin] | [1] Vigabatrin Vigabatrin | [1] Vigabatrin
Vigabatrin
💬
| [1] ABAT ABAT 💬
| [6] Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | [1] 145 145 💬
|
| 1407 | [vitamina D e calcio] | [1] Calcium Calcium | - | - | - | [1] 274 274 💬
|
| 1408 | [VO659] | [1] VO659 VO659 | - | - | - | [2] 8 8, 18 💬
|
| 1409 | [volixibat] | [1] Volixibat Volixibat | [2] Volixibat potassium
Volixibat potassium
,
Volixibat
💬
| - | - | [1] 93 93 💬
|
| 1410 | [VTX002] | - | - | - | - | [1] 97 97 💬
|
| 1411 | [VTX958] | - | - | - | - | [1] 96 96 💬
|
| 1412 | [VX-121/TEZ/D-IVA] | - | - | - | - | [1] 299 299 💬
|
| 1413 | [VX-445/TEZ/IVA] | - | - | - | - | [1] 299 299 💬
|
| 1414 | [VX-661 / VX-770] | - | - | - | - | [1] 299 299 💬
|
| 1415 | [VX-770] | - | - | - | - | [1] 299 299 💬
|
| 1416 | [VXT002] | - | - | - | - | [1] 97 97 💬
|
| 1417 | [WVE-003] | [1] WVE-003 WVE-003 | - | - | - | [1] 8 8 💬
|
| 1418 | [WVE-210201] | - | - | - | - | [1] 113 113 💬
|
| 1419 | [X4P-001] | - | - | - | - | [1] 65 65 💬
|
| 1420 | [XmAb5871] | - | - | - | - | [1] 300 300 💬
|
| 1421 | [YKP509] | - | - | - | - | [1] 144 144 💬
|
| 1422 | [Z7219] | - | - | - | - | [1] 17 17 💬
|
| 1423 | [ZN-d5] | - | - | - | - | [1] 28 28 💬
|
| 1424 | [Zr-89]Oxine-labeled leukocytes PET/MRI | - | - | - | - | [1] 13 13 💬
|
| 1425 | [ZX008] | - | - | - | - | [2] 140 140, 144 💬
|
| 1426 | [ZYTIGA] | - | - | - | - | [1] 75 75 💬
|
| 1427 | [¹8F]MODAG-009 PET imaging | - | - | - | - | [2] 6 6, 17 💬
|
| 1428 | LNP023 | - | - | - | - | [1] 223 223 💬
|
| 1429 | LNP023 hydrochloride | - | - | - | - | [1] 223 223 💬
|
| 1430 | LNP023 HYDROCHLORIDE SALT | - | - | - | - | [7] 61 61, 62, 63, 66, 109, 222, 223 💬
|
| 1431 | ¹8F-florbetaben | - | - | - | - | [1] 28 28 💬
|
| 1432 | ÁCIDO GADOBÉNICO | - | - | - | - | [1] 96 96 💬
|
| 1433 | Ácido risedrónico | - | - | - | - | [1] 274 274 💬
|